Methods for synthesizing substituted pyridinone-pyridinyl compounds

JP2023553814A5Inactive Publication Date: 2024-11-26ACLARIS THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023531003
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-01
Filing Date
2021-11-23
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for synthesizing substituted pyridinone-pyridinyl compounds face challenges in efficiently producing individual atropisomers, which are stereoisomers that result from constrained rotation about a single bond, due to high steric strain barriers, leading to difficulties in isolation and separation.

Method used

The method involves chiral resolution and synthesis routes that include chiral separation steps to produce individual atropisomers of substituted pyridinone-pyridinyl compounds, utilizing various intermediates and reagents such as chiral auxiliaries and chromatographic methods like simulated moving bed chromatography with chiral stationary phases.

Benefits of technology

This approach allows for the efficient production of pure or enriched atropisomers, which can exhibit different biological activities, addressing the challenge of isolating and separating these stereoisomers effectively.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022109481000001
    Figure 2022109481000001
  • Figure 2022109481000002
    Figure 2022109481000002
  • Figure 2022109481000003
    Figure 2022109481000003
Patent Text Reader

Abstract

This disclosure provides methods for synthesizing compounds of formula (P)-I. The methods proceed via various halide-containing intermediates by several different routes, including several novel chiral separations, Sonogashira couplings, and zinc-mediated reductive cyanations. Multikilogram preparations of several novel intermediates are also disclosed. JPEG2023553814000334.jpg5955
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 117,053, filed November 23, 2020, and U.S. Provisional Patent Application No. 63 / 239,596, filed September 1, 2021, the disclosures of each of which are incorporated herein by reference. [Background technology]

[0002] Summary of the Invention

[0003] The present disclosure provides a structure [ka]

[0023] Embodiments include those directed to methods of synthesizing compounds of formula (P)-I having the formula: The method involves chiral resolution to produce a compound of formula (P)-I, or alternatively, several different intermediates in the synthesis of formula (P)-I. Alternative syntheses of several intermediates are also disclosed.

[0004] definition Before describing the compositions and methods, it is to be understood that this invention is not limited to the particular methods, formulations, compositions, or procedures described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular versions or embodiments only, and is not intended to limit the scope of the embodiments herein, which are limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the embodiments herein, the preferred methods, devices, and materials are now described. All publications cited herein are incorporated by reference in their entirety. Nothing herein should be construed as an admission that the embodiments herein are not entitled to antedate such disclosure by virtue of prior invention. It should also be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. The transitional phrase "comprising," which is synonymous with "including," "containing," or "featuring," is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.

[0005] In embodiments or claims where the term "comprising" is used as a transitional phrase, such embodiments can also be construed by replacing the term "comprising" with the term "consisting of" or "consisting essentially of." As used herein, the terms "consists of" or "consisting of" mean that a composition, formulation, or method includes only those elements, steps, or materials specifically recited in a particular claimed embodiment or claim.

[0006] As used herein, the terms "consisting essentially of" or "consists essentially of" mean that a composition, formulation, or method includes only the elements, steps, or materials specifically recited in a particular claimed embodiment or claim, and may include additional elements, steps, or materials that do not materially affect the basic and novel characteristics of the particular embodiment or claim. For example, the only active ingredient in a formulation or method for treating a specified condition (e.g., nutrient deficiency) is a therapeutic agent specifically recited in a particular embodiment or claim. As used herein, two embodiments are "mutually exclusive" when one is defined as something different from the other. For example, an embodiment in which two groups combine to form a cycloalkyl is mutually exclusive from an embodiment in which one group is ethyl and the other group is hydrogen. Similarly, an embodiment in which one group is CH2 is mutually exclusive from an embodiment in which the same group is NH.

[0007] When ranges of values ​​are disclosed and the notation "from n1 to n2" or "between n1 and n2" (where n1 and n2 are numbers) is used, unless otherwise specified, this notation is intended to include the numbers themselves and the range between the numbers. The range can be fractional or continuous, both between and including the end values. As an example, the range "2 to 6 carbons" is intended to include 2, 3, 4, 5, and 6 carbons, since carbon is an integer unit. As an example, compare the range "1 to 3 μM (micromolar)" which is intended to include 1 μM, 3 μM, and all intermediate values ​​of any significant digit (e.g., 1.255 μM, 2.1 μM, 2.9999 μM, etc.). As used herein, the term "about" is intended to modify the numerical value it modifies and expresses such values ​​as variable within a margin of error. When a specific error range, such as the standard deviation for the average value stated in a data chart or table, is not specified, the term "about" should be understood to mean a numerical value of ±10% of the number with which it is used. Thus, about 50% means a range of 45% to 55%. In embodiments or claims, "X" in the term "MeMgX" is a halogen. As used herein, the term "chiral separation" refers to the separation of racemic compounds into their single or enriched atropisomers or enantiomers. The term "substantially free," as used herein, is used interchangeably with the term "substantially pure" and refers to a compound that is free of all other compounds within the limits of detection as measured by any means, including nuclear magnetic resonance (NMR), gas chromatography / mass spectrometry (GC / MS), or liquid chromatography / mass spectrometry (LC / MS). In some embodiments, substantially free can be less than about 1.0%, less than about 0.5%, less than about 0.4%, less than about 0.3%, less than about 0.2%, less than about 0.1%, less than about 0.05%, or less than about 0.01%. The term "interconversion" or "conformational interconversion" refers to any transformation between atropisomers of the present disclosure, including but not limited to equilibration.

[0008] The term "equilibrium" refers to a chemical reaction in which the forward and reverse rates balance out. Equilibrium can be dynamic or static. A reaction at equilibrium need not contain equal amounts of reactants and products. When referring to atropisomeric compounds, the term "equilibrium" refers to when the rates of interconversion balance out. Atropisomers at equilibrium need not contain equal amounts of each single atropisomer, and include racemic mixtures of atropisomers, enriched mixtures of atropisomers, and single atropisomers.

[0009] Embodiments are also provided in which any embodiment herein can be combined with any one or more of the other embodiments, unless otherwise stated, and provided that the combinations are not mutually exclusive. Atropisomers are stereoisomers resulting from restricted rotation around a single bond, where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers. Oki (Oki, M; Topics in Stereochemistry, 1983, 1) defined atropisomers as conformers that interconvert with half-lives of greater than 1000 seconds at a given temperature. The scope of the described and claimed embodiments herein encompasses racemic forms of compounds as well as individual atropisomers (those atropisomers that are "substantially free" of the corresponding atropisomer) and stereoisomer-enriched mixtures, i.e., mixtures of atropisomers. Separation of atropisomers is likely by chiral resolution techniques such as selective crystallization. In atropo-enantioselective or atroposelective synthesis, one atropisomer is formed at the expense of the other. Atroposelective synthesis can be achieved by the use of chiral auxiliaries, such as the Corey-Bakshi-Shibata (CBS) catalyst (a proline-derived asymmetric catalyst) in the total synthesis of kniphorone, or by methods based on thermodynamic equilibration when one atropisomer is favored in an isomerization reaction over the other. The term "atropisomerism" refers to a type of isomerism resulting from restricted rotation around a single bond due to steric strain of substituents. This phenomenon creates stereoisomers that exhibit axial chirality.

[0010] The following scheme illustrates "atropisomerism" with reference to specific pyridinone-pyridine compounds of the invention. [ka]

[0011] The bond between the B and C rings of the title compound is constrained and does not allow for easy rotation. The steric strain barrier to rotation is high enough to allow for the isolation of individual conformers. The compounds of the present invention can also exist as atropisomers, i.e., chiral rotamers. The present invention encompasses racemates, resolved atropisomers, and mixtures thereof. Atropisomers can be separated by various chromatographic methods, including but not limited to supercritical fluid chromatography using carbon dioxide and ethanol / methanol mobile phases and simulated moving bed (SMB) chromatography with chiral stationary and mobile phases.

[0012] Atropisomers are generally stable, but can often undergo thermal equilibration. Atropisomers have the same but opposite optical rotation. Each atropisomer may have different properties when binding to an enzyme or receptor, with one isomer often being more potent than the other. Atropisomers are frequently used as drugs. Known examples include vancomycin and derivatives.

[0013] The configurations of atropisomers can be described using the nomenclature (M)- and (P)- to describe the relative positions of substituents, as described in Bringmann, G. et al., Angew. Chem. Int. Ed. 2005, 44, 5384 and references cited therein. Although the structures are designated as drawn, it is understood that the (P)- or (M)-isomer may be desired, and the methods described are useful for the interconversion of the (P)- or (M)-stereoisomers. DETAILED DESCRIPTION OF THE INVENTION

[0014] The present disclosure provides a compound of formula (P)-I having the following structure: [ka] The present invention includes embodiments directed to methods of synthesizing Scheme 1 outlines Routes A, B, C, D, and H for synthesizing compounds of Formula (P)-I. Each of these routes features chiral separation of an intermediate, followed by driving a single or enriched atropisomer through the remainder of the synthesis of compounds of Formula (P)-I.

[0015] Scheme 1 [ka]

[0016] In some embodiments, the process for preparing a compound of formula (P)-I proceeds via Path A as follows: SM-01 and SM-02 are contacted to obtain CPD-01, CPD-01 is converted to CPD-02, CPD-02 and INT-01 are contacted to obtain CPD-03, CPD-03 is converted to CPD-04, CPD-04 is converted to CPD-05, CPD-05 is converted to CPD-06, CPD-06 is subjected to chiral separation to obtain CPD-07, CPD-07 is converted to CPD-08, CPD-08 is converted to CPD-09, CPD-09 is converted to CPD-10, and then CPD-10 and INT-02 are contacted to obtain formula P-(I).

[0017] In some embodiments, the process for preparing a compound of formula (P)-I proceeds via Path B as follows: SM-01 and SM-02 are contacted to obtain CPD-01, CPD-01 is converted to CPD-02, CPD-02 and INT-01 are contacted to obtain CPD-03, CPD-03 is converted to CPD-11, CPD-11 is subjected to chiral separation to obtain CPD-12, CPD-12 is converted to CPD-07, CPD-07 is converted to CPD-08, CPD-08 is converted to CPD-09, CPD-09 is converted to CPD-10, and then CPD-10 and INT-02 are contacted to obtain a compound of formula P-(I).

[0018] In some embodiments, the process for preparing a compound of formula (P)-I proceeds via Path C as follows: SM-01 and SM-02 are contacted to obtain CPD-01, CPD-01 is converted to CPD-02, CPD-02 and INT-01 are contacted to obtain CPD-03, CPD-03 is converted to CPD-11, CPD-11 is subjected to chiral separation to obtain CPD-12, CPD-12 is converted to CPD-13, CPD-13 is converted to CPD-08, CPD-08 is converted to CPD-09, CPD-09 is converted to CPD-10, and then CPD-10 and INT-02 are contacted to obtain formula P-(I).

[0019] In some embodiments, the process for preparing a compound of formula (P)-I proceeds via Path D as follows: SM-01 and SM-02 are contacted to obtain CPD-01, CPD-01 is converted to CPD-02, CPD-02 and INT-01 are contacted to obtain CPD-03, CPD-03 is converted to CPD-11, CPD-11 is subjected to chiral separation to obtain CPD-12, CPD-12 is converted to CPD-13, CPD-13 is converted to CPD-14, CPD-14 is converted to CPD-09, CPD-09 is converted to CPD-10, and then CPD-10 and INT-02 are contacted to obtain formula P-(I).

[0020] In some embodiments, the method for preparing a compound of Formula (P)-I proceeds via Route H as follows: contacting SM-01 and SM-02 to obtain CPD-01, converting CPD-01 to CPD-02, contacting CPD-02 and INT-01 to obtain CPD-03, converting CPD-03 to CPD-04, converting CPD-04 to CPD-11, and subjecting CPD-11 to chiral separation to obtain CPD-12. CMP-12 is then carried forward to Formula P-(I) via the synthetic sequence described in Route B, Route C, or Route D. Scheme 2 outlines Routes E, F, and G for synthesizing compounds of Formula (P)-I. Each of these routes features a chiral separation as the final step in the synthesis of compounds of Formula (P)-I.

[0021] Scheme 2 [ka]

[0022] In some embodiments, the process for preparing a compound of formula (P)-I proceeds via Path E as follows: SM-01 and SM-02 are contacted to obtain CPD-01, CPD-01 is converted to CPD-02, CPD-02 and INT-01 are contacted to obtain CPD-03, CPD-03 is converted to CPD-15, CPD-15 is converted to CPD-16, CPD-16 is converted to CPD-18, CPD-18 is converted to CPD-19, CPD-19 and INT-02 are contacted to obtain CPD-20, and then CPD-20 is subjected to chiral separation to obtain formula P-(I). In some embodiments, the process for preparing a compound of formula (P)-I proceeds via Path F as follows: SM-01 and SM-02 are contacted to obtain CPD-01, CPD-01 is converted to CPD-02, CPD-02 and INT-01 are contacted to obtain CPD-03, CPD-03 is converted to CPD-17, CPD-17 is converted to CPD-18, CPD-18 is converted to CPD-19, CPD-19 and INT-02 are contacted to obtain CPD-20, and then CPD-20 is subjected to chiral separation to obtain formula P-(I). In some embodiments, the process for preparing a compound of formula (P)-I proceeds via Path G as follows: SM-01 and SM-02 are contacted to obtain CPD-01, CPD-01 is converted to CPD-02, CPD-02 and INT-01 are contacted to obtain CPD-03, CPD-03 is converted to CPD-15, CPD-15 is converted to CPD-17, CPD-17 is converted to CPD-18, CPD-18 is converted to CPD-19, CPD-19 and INT-02 are contacted to obtain CPD-20, and then CPD-20 is subjected to chiral separation to obtain formula P-(I). Scheme 3 outlines a method for synthesizing compounds of formula (P)-I.

[0023] Scheme 3 [ka] Scheme alpha outlines a method for synthesizing compounds of formula (P)-I.

[0024] Scheme Alpha [ka]

[0025] Another embodiment of the present disclosure is directed to compounds of formula (P)-I prepared according to Routes A, B, C, D, and H shown in Scheme 1; Routes E, F, and G shown in Scheme 2; the route shown in Scheme 3, and the route shown in Scheme Alpha.

[0026] Some embodiments of the present application relate to a compound of formula (P)-I having the following structure: [ka] A method for preparing (a) compound [ka] in the presence of dimethylacetemide (DMAc) [ka] to form a mixture; (b) contacting the mixture of (a) with an alcoholic HCl solution to form the compound [ka] forming a (c) converting CPD-01 to formula (P)-I; The method is described, comprising:

[0027] In some embodiments of the formation of CPD-01, the alcoholic HCl solution is selected from the group consisting of an isopropyl alcohol HCl solution or p-toluenesulfonic acid in dimethylacetamide (DMAc). In some embodiments of the formation of CPD-01, the alcoholic HCl solution is an isopropyl alcohol HCl solution. In another embodiment of the process for preparing formula (P)-I, the process comprises contacting compound CPD-01 with H2SO4 to obtain compound [ka] The method further includes forming a

[0028] In another embodiment of the process for preparing formula (P)-I, the process comprises reacting compound CPD-02 with compound [ka] and a base to form the compound [ka] The method further includes forming a

[0029] In some embodiments of forming CPD-03, the base is selected from the group consisting of K2CO3, NaOH, Cs2CO3, and NaHCO3. In some embodiments, the base used to form CPD-03 is selected from the group consisting of K2CO3 and Cs2CO3. In some embodiments of forming CPD-03, the base is K2CO3. In some embodiments, the base used to form CPD-03 is Cs2CO3.

[0030] In some embodiments of the process for preparing Formula (P)-I, the process includes contacting compound CPD-03 with CO in the presence of a palladium catalyst, an amine base, and methanol to produce compound CPD-03.

[0031] [ka] The method further includes forming a

[0032] In some embodiments of the formation of CPD-04, the palladium catalyst is selected from the group consisting of Pd(dppf)Cl, Pd(OAc) / Bis(diphenylphosphino)propane (DPPP), Pd(PPh)Cl, Pd(OAc) / Xphos, Pd(OAc) / Ruphos, Pd(DTBPF)Cl, and (BINAP)PdCl.

[0033] In some embodiments of the formation of CPD-04, the palladium catalyst is Pd(dppf)Cl 2 . In some embodiments of the formation of CPD-04, the amine base is selected from the group consisting of triethylamine, iPr2NEt, and tetramethylethylenediamine. In some embodiments of the formation of CPD-04, the amine base is triethylamine. In some embodiments of the process for preparing Formula (P)-I, the process includes contacting compound CPD-04 with a chlorinating reagent to obtain compound [ka] The method further includes forming a In some embodiments of the formation of CPD-05, the chlorinating reagent is N-chlorosuccinimide. In some embodiments, the formation of CPD-05 further comprises contacting CPD-04 with dichloroacetic acid.

[0034] In some embodiments of the process for preparing Formula (P)-I, the process comprises hydrolyzing and desalting compound CPD-05 to obtain compound (P)-I. [ka] The method further includes forming a

[0035] In some embodiments of the process for preparing Formula (P)-I, the process comprises subjecting compound CPD-06 to chiral separation using a chiral amine and a solvent to obtain compound [ka] The method further includes the step of obtaining:

[0036] In some embodiments of the chiral separation of compound CPD-06, the chiral amine is selected from the group consisting of (S)-1-(naphthalen-2-yl)ethan-1-amine and (1S,2R)-2-amino-1,2-diphenylethan-1-ol. In some embodiments of the chiral separation of compound CPD-06, the chiral amine is (S)-1-(naphthalen-2-yl)ethan-1-amine. In some embodiments of the chiral separation of compound CPD-06, the chiral amine is (1S,2R)-2-amino-1,2-diphenylethan-1-ol. In some embodiments of the chiral separation of compound CPD-06, the solvent is selected from the group consisting of toluene, ethylbenzene, n-butanol, anisole, DMSO, or a combination thereof. In some embodiments of the chiral separation of compound CPD-06, the solvent is toluene. In some embodiments of the chiral separation of compound CPD-06, the solvent is ethylbenzene. In some embodiments of the chiral separation of compound CPD-06, the solvent is n-butanol. In some embodiments of the chiral separation of compound CPD-06, the solvent is anisole. In some embodiments of the chiral separation of compound CPD-06, the solvents are anisole and DMSO.

[0037] In some embodiments of the process for preparing Formula (P)-I, the process includes contacting compound CPD-07 with a solvent, MeNHOMe, an amine base, and a coupling reagent to obtain compound CPD-07.

[0038] [ka] The method further includes the step of obtaining: In some embodiments in which compound CPD-07 is contacted, the solvent is selected from DMF, dichloromethane, or a combination thereof. In some embodiments in which compound CPD-07 is contacted, the solvent is DMF. In some embodiments in which compound CPD-07 is contacted, the solvent is dichloromethane. In some embodiments in which compound CPD-07 is contacted, the amine base is triethylamine. In some embodiments where compound CPD-07 is contacted, the coupling reagent is N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride.

[0039] In some embodiments of the method for preparing Formula (P)-I, the method includes contacting compound CPD-08 with MeMgX to obtain the compound [ka] The method further includes the step of obtaining: In some embodiments in which compound CPD-07 is contacted, MeMgX is selected from the group consisting of MeMgBr and MeMgCl. In some embodiments in which compound CPD-07 is contacted, MeMgX is MeMgBr. In some embodiments in which compound CPD-07 is contacted, MeMgX is MeMgCl. In some embodiments of the method for preparing Formula (P)-I, the method comprises condensing compound CPD-09 with N,N-dimethyl-formamide dimethyl acetal to produce the compound

[0040] [ka] The method further includes the step of obtaining:

[0041] In some embodiments of the process for preparing Formula (P)-I, the process comprises reacting compound CPD-10 with [ka] and forming a compound of formula (P)-I. In some embodiments of forming a compound of Formula (P)-I, the base is selected from the group consisting of K2CO3, N,N-diisopropylethylamine (DIPEA), triethylamine (TEA), tBuOK, tBuONa, and Cs2CO3.

[0042] In some embodiments of forming a compound of formula (P)-I, the base is K2CO3. Scheme 4 outlines an alternative method for synthesizing CPD-07, CPD-08, and CPD-09 starting from CPD-03. CPD-07, CPD-08, and CPD-09 can then each be carried forward with the remainder of the sequence outlined in Scheme 3 to produce compounds of formula P-(I).

[0043] Scheme 4 [ka] The formation of CPD-04 from CPD-03 is as disclosed above. According to Scheme 4, in some embodiments, the method for preparing Formula (P)-I includes contacting compound CPD-03 with CO in the presence of a palladium catalyst, an amine base, and DMF / HO to obtain the compound

[0044] [ka] The method includes forming a

[0045] In some embodiments of forming CPD-11, the palladium catalyst is (BINAP)PdCl 2 .

[0046] In some embodiments of forming CPD-11, the amine base is triethylamine. According to Scheme 4, in some embodiments, the method for preparing Formula (P)-I comprises: (a) contacting compound CPD-03 with CO in the presence of a palladium catalyst, an amine base, a first base, and MeOH / HO to form a mixture; (b) contacting the mixture of (a) with a second base to form the compound [ka] forming a Includes. In some embodiments of forming CPD-11, the palladium catalyst is Pd(dppf)Cl 2 ·DCM. In some embodiments of forming CPD-11, the amine base is triethylamine.

[0047] In some embodiments of forming CPD-11, the first base is Na2CO3. In some embodiments of forming CPD-11, the second base is NaOH. In some embodiments of the process for preparing Formula (P)-I, the process includes contacting compound CPD-04 with a base to obtain the compound [ka] The method further includes forming a In some embodiments of forming CPD-11, the base is selected from LiOH or NaOH. In some embodiments of forming CPD-11, the base is LiOH. In some embodiments of forming CPD-11, the base is NaOH.

[0048] In some embodiments of the process for preparing Formula (P)-I, the process comprises subjecting compound CPD-11 to chiral separation using a chiral amine and a solvent to obtain compound CPD-11. [ka] The method further includes the step of obtaining:

[0049] In some embodiments of the chiral separation of compound CPD-11, the chiral amine is selected from the group consisting of (S)-1-(naphthalen-2-yl)ethan-1-amine and (1S,2R)-2-amino-1,2-diphenylethan-1-ol. In some embodiments of the chiral separation of compound CPD-11, the chiral amine is (S)-1-(naphthalen-2-yl)ethan-1-amine. In some embodiments of the chiral separation of compound CPD-11, the chiral amine is (1S,2R)-2-amino-1,2-diphenylethan-1-ol. In some embodiments of the chiral separation of compound CPD-11, the solvent is selected from the group consisting of toluene, ethylbenzene, n-butanol, anisole, DMSO, or a combination thereof. In some embodiments of the chiral separation of compound CPD-11, the solvent is toluene.

[0050] In some embodiments of the chiral separation of compound CPD-11, the solvent is ethylbenzene. In some embodiments of the chiral separation of compound CPD-11, the solvent is n-butanol. In some embodiments of the chiral separation of compound CPD-11, the solvent is anisole. In some embodiments of the chiral separation of compound CPD-11, the solvents are anisole and DMSO.

[0051] In some embodiments of the process for preparing Formula (P)-I, the process includes contacting compound CPD-12 with a chlorinating reagent to obtain compound CPD-12. [ka] The method further includes forming a

[0052] In some embodiments of forming CPD-07, the chlorinating reagent is N-chlorosuccinimide. In some embodiments, the formation of CPD-07 further comprises contacting CPD-12 with dichloroacetic acid. In another embodiment of the process for preparing Formula (P)-I, the process includes contacting compound CPD-12 with a solvent, MeNHOMe, an amine base, and a coupling reagent to obtain compound CPD-12. [ka] The method further includes the step of obtaining: In some embodiments in which compound CPD-12 is contacted, the solvent is selected from DMF, dichloromethane, or a combination thereof.

[0053] In some embodiments in which compound CPD-12 is contacted, the solvent is DMF. In some embodiments in which compound CPD-12 is contacted, the solvent is dichloromethane. In some embodiments in which compound CPD-12 is contacted, the amine base is triethylamine. In some embodiments where compound CPD-12 is contacted, the coupling reagent is N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride.

[0054] In some embodiments of the process for preparing Formula (P)-I, the process includes contacting compound CPD-13 with a chlorinating reagent to obtain compound CPD-13. [ka] The method further includes forming a

[0055] In some embodiments of the formation of CPD-08, the chlorinating reagent is N-chlorosuccinimide. In some embodiments, the formation of CPD-08 further comprises contacting CPD-13 with dichloroacetic acid. In another embodiment of the process for preparing formula (P)-I, the process comprises contacting compound CPD-13 with MeMgX to obtain compound [ka] The method further includes the step of obtaining: In some embodiments of contacting compound CPD-13, MeMgX is selected from the group consisting of MeMgBr and MeMgCl.

[0056] In some embodiments in which compound CPD-13 is contacted, MeMgX is MeMgBr. In some embodiments in which compound CPD-13 is contacted, MeMgX is MeMgCl. In some embodiments of the process for preparing Formula (P)-I, the process includes contacting compound CPD-14 with a chlorinating reagent to obtain compound [ka] The method further includes forming a In some embodiments of the formation of CPD-09, the chlorinating reagent is N-chlorosuccinimide. In some embodiments, the formation of CPD-09 further comprises contacting CPD-14 with dichloroacetic acid. Scheme 5 outlines an alternative synthesis of formula (P)-I starting from CPD-03 via CPD-15 or CPD-17. Chiral separation is used to generate formula (P)-I.

[0057] Scheme 5 [ka]

[0058] According to the method described in Scheme 5, the method for preparing the compound (P)-I is to contact the compound CPD-03 with MeNH(OMe) HCl in the presence of a palladium catalyst, a phosphorus reagent, CO, and a base to obtain the compound [ka] The method includes forming a

[0059] In some embodiments of forming CPD-15, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-15, the phosphorus reagent is Xantphos. In some embodiments of forming CPD-15, the base is Na2CO3. In some embodiments of the method for preparing Formula (P)-I, the method includes contacting compound CPD-15 with MeMgX to obtain the compound [ka] The method further includes the step of obtaining:

[0060] In some embodiments of contacting compound CPD-15, MeMgX is selected from the group consisting of MeMgBr and MeMgCl. In some embodiments in which compound CPD-15 is contacted, MeMgX is MeMgBr. In some embodiments in which compound CPD-15 is contacted, MeMgX is MeMgCl. In another embodiment of the process for preparing Formula (P)-I, the process comprises contacting compound CPD-15 with a chlorinating reagent to obtain compound [ka] The method further includes forming a

[0061] In some embodiments of the formation of CPD-16, the chlorinating reagent is N-chlorosuccinimide. In some embodiments, the formation of CPD-16 further comprises contacting CPD-15 with dichloroacetic acid. In another embodiment of the process for preparing formula (P)-I, the process comprises contacting compound CPD-16 with MeMgX to obtain compound [ka] The method further includes the step of obtaining:

[0062] In some embodiments in which compound CPD-16 is contacted, MeMgX is selected from the group consisting of MeMgBr and MeMgCl. In some embodiments in which compound CPD-16 is contacted, MeMgX is MeMgBr. In some embodiments in which compound CPD-16 is contacted, MeMgX is MeMgCl. According to Scheme 5, in another embodiment of the process for preparing Formula (P)-I, the process comprises: (a) contacting compound CPD-03 with a vinyltin reagent in the presence of a palladium catalyst to form a mixture; (b) contacting the mixture of (a) with HCl to form the compound

[0063] [ka] forming a Also includes:

[0064] In some embodiments of forming CPD-17, the vinyltin reagent is [ka] is. In some embodiments of forming CPD-17, the palladium catalyst is PdCl2(PPh3)2. According to the method described in Scheme 5, the preparation of formula (P)-I also includes an alternative method of converting CPD-03 to CPD-17. The method involves contacting compound CPD-03 with butyl vinyl ether in the presence of a palladium catalyst, a phosphorus reagent, and a base to give compound (P)-I. [ka] The method includes forming a

[0065] In some embodiments of forming CPD-27, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-27, the phosphorus reagent is 1,1'-ferrocenediyl-bis(diphenylphosphine) (dppf). In some embodiments forming CPD-27, the base is iPr2NEt. In some embodiments of the process for preparing Formula (P)-I, the process includes contacting compound CPD-27 with an acid to obtain compound CPD-27. [ka] The method further includes forming a

[0066] In some embodiments of forming CPD-17, the acid is HCl. In some embodiments of the process for preparing Formula (P)-I, the process comprises reacting compound CPD-17 with The compound is contacted with a chlorinating agent. [ka] The method further includes forming a

[0067] In some embodiments of the formation of CPD-18, the chlorinating reagent is N-chlorosuccinimide. In some embodiments, the formation of CPD-18 further comprises contacting CPD-17 with dichloroacetic acid. According to Scheme 5, whether the process proceeds via the formation of CPD-17 as described above or via the formation of CPD-15, the process for preparing formula (P)-I involves condensing compound CPD-18 with N,N-dimethyl-formamide dimethyl acetal to give compound [ka] The method further includes the step of obtaining:

[0068] In some embodiments of the condensation of the compound CPD-18, the condensation further comprises L-proline. In another embodiment of the process for preparing Formula (P)-I, the process comprises: Compound CPD-19 in the presence of a base [ka] and contacting the compound [ka] forming a Further includes:

[0069] In some embodiments of forming a compound of CPD-20, the base is selected from the group consisting of K2CO3, N,N-diisopropylethylamine (DIPEA), triethylamine (TEA), tBuOK, tBuONa, and Cs2CO3. In some embodiments of the formation of CPD-20, the base is K2CO3. In another embodiment of the method for preparing formula (P)-I, the method further comprises subjecting compound CPD-20 to chromatographic separation to obtain the compound of formula (P)-I. In some embodiments of the process for preparing Formula (P)-I, the chromatographic separation comprises simulated moving bed (SMB) chromatography with a chiral stationary phase and a mobile phase.

[0070] In some embodiments of the process for preparing Formula (P)-I, the chiral stationary phase is selected from the group consisting of Chiralpak® AD, Chiralpak® AS, Chiralpak® AY, Chiralpak® AZ, Chiralpak® OD, Chiralpak® OZ, Chiralpak® IA, Chiralpak® IB-N, Chiralpak® IC, Chiralpak® ID, Chiralpak® IE, Chiralpak® IF, Chiralpak® IG, and Chiralpak® IH. In some embodiments of the process for preparing Formula (P)-I, the chiral stationary phase is Chiralpak® IB-N. In some embodiments of the process for preparing Formula (P)-I, the mobile phase is selected from the group consisting of acetonitrile, methanol, acetonitrile and methanol, n-heptane and ethanol, n-heptane and dichloromethane, n-heptane and ethyl acetate, dichloromethane and methanol, and dichloromethane and acetonitrile.

[0071] In some embodiments of the process for preparing Formula (P)-I, the mobile phase is dichloromethane and acetonitrile. In some embodiments of the method for preparing Formula (P)-I, when the mobile phase is in the form of a mixture, the mixture can be in a volume ratio of about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 7:3, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 3:7, or any ratio intermediate therebetween.

[0072] compound [ka] The method for preparing the compound [ka] is subjected to chiral separation using a chiral amine and solvent to obtain compound CPD-07.

[0073] In some embodiments of the chiral separation of compound CPD-06, the chiral amine is selected from the group consisting of (S)-1-(naphthalen-2-yl)ethan-1-amine and (1S,2R)-2-amino-1,2-diphenylethan-1-ol. In some embodiments of the chiral separation of compound CPD-06, the chiral amine is (S)-1-(naphthalen-2-yl)ethan-1-amine. In some embodiments of the chiral separation of compound CPD-06, the chiral amine is (1S,2R)-2-amino-1,2-diphenylethan-1-ol. In some embodiments of the chiral separation of compound CPD-06, the solvent is selected from the group consisting of toluene, ethylbenzene, n-butanol, anisole, DMSO, or a combination thereof. In some embodiments of the chiral separation of compound CPD-06, the solvent is toluene.

[0074] In some embodiments of the chiral separation of compound CPD-06, the solvent is ethylbenzene. In some embodiments of the chiral separation of compound CPD-06, the solvent is n-butanol. In some embodiments of the chiral separation of compound CPD-06, the solvent is anisole. In some embodiments of the chiral separation of compound CPD-06, the solvents are anisole and DMSO.

[0075] compound [ka] The method for preparing the compound [ka] is subjected to chiral separation using a chiral amine and solvent to give compound CPD-12.

[0076] In some embodiments of the chiral separation of compound CPD-11, the chiral amine is selected from the group consisting of (S)-1-(naphthalen-2-yl)ethan-1-amine and (1S,2R)-2-amino-1,2-diphenylethan-1-ol. In some embodiments of the chiral separation of compound CPD-11, the chiral amine is (S)-1-(naphthalen-2-yl)ethan-1-amine. In some embodiments of the chiral separation of compound CPD-11, the chiral amine is (1S,2R)-2-amino-1,2-diphenylethan-1-ol. In some embodiments of the chiral separation of compound CPD-11, the solvent is selected from the group consisting of toluene, ethylbenzene, n-butanol, anisole, DMSO, or a combination thereof.

[0077] In some embodiments of the chiral separation of compound CPD-11, the solvent is toluene. In some embodiments of the chiral separation of compound CPD-11, the solvent is ethylbenzene. In some embodiments of the chiral separation of compound CPD-11, the solvent is n-butanol. In some embodiments of the chiral separation of compound CPD-11, the solvent is anisole. In some embodiments of the chiral separation of compound CPD-11, the solvents are anisole and DMSO. Scheme 6 outlines an alternative route to synthesize formula (P)-I starting from CPD-03 using Sonogashira coupling. Chiral separation is used to generate formula (P)-I.

[0078] Scheme 6 [ka]

[0079] According to Scheme 6, some embodiments of the present application provide a compound of formula (P)-I having the following structure: [ka] A method for preparing [ka] and propargyl alcohol are subjected to Sonogashira coupling reaction in the presence of a palladium catalyst and a base to give the compound [ka] forming a converting CPD-21 to formula (P)-I; The method includes the method comprising:

[0080] In some embodiments of the Sonogashira coupling of CPD-03, the palladium catalyst is Pd(PPh3)4. In some embodiments of the Sonogashira coupling of CPD-03, the amine base is triethylamine. In some embodiments of the method for preparing Formula (P)-I, the method comprises oxidizing compound CPD-21 with an oxidizing agent to obtain compound [ka] The method further includes forming a

[0081] In some embodiments of the oxidation of CPD-21, the oxidizing agent is Dess-Martin periodinane.

[0082] In some embodiments of the process for preparing Formula (P)-I, the process comprises reacting compound CPD-22 in the presence of a base [ka] and contacting the compound [ka] forming a Further includes:

[0083] In some embodiments of the formation of CPD-23, the base is Na2CO3. In some embodiments of the process for preparing Formula (P)-I, the process includes contacting compound CPD-23 with a chlorinating reagent to obtain compound CPD-23. [ka] The method further includes forming a

[0084] In some embodiments of the chlorination of CPD-23, the chlorinating reagent is N-chlorosuccinimide. In some embodiments, the formation of CPD-20 further comprises contacting CPD-23 with dichloroacetic acid.

[0085] In some embodiments of the method for preparing Formula (P)-I, the method further comprises subjecting compound CPD-20 to chiral chromatography to obtain the compound of Formula (P)-I. Scheme 7 shows an alternative method for synthesizing CPD-17 starting from CPD-03. The CPD-03 so utilized can be derived from any of the embodiments described herein that produce CPD-03. CPD-17 so generated can be used in any of the embodiments disclosed herein that utilize CPD-17.

[0086] Scheme 7 [ka] Thus, some embodiments of the present application provide compounds [ka] A method for preparing the compound [ka] is contacted with Pd2(dba)3 and Zn(CN)2 to form the compound [ka] and converting CPD-24 to CPD-17.

[0087] In another embodiment of the method for preparing compound CPD-17, the method comprises contacting compound CPD-24 with MeMgX to provide compound CPD-17. In some embodiments of the contacting of compound CPD-17, MeMgX is selected from the group consisting of MeMgBr, MeMgCl, and MeMgI. In some embodiments of the contacting of compound CPD-17, MeMgX is MeMgBr. In some embodiments of the contacting of compound CPD-17, MeMgX is MeMgCl.

[0088] In some embodiments of the contact of compound CPD-17, MeMgX is MeMgI. Scheme 8 shows an alternative method for synthesizing CPD-04 starting from CPD-02 via a bromine-containing intermediate. The CPD-02 so utilized can be derived from any of the embodiments described herein that produce CPD-02. The CPD-04 so generated can be used in any of the embodiments disclosed herein that utilize CPD-04.

[0089] Scheme 8 [ka]

[0090] According to Scheme 8, some embodiments of the present application comprise the compound [ka] A method for preparing the compound [ka] is contacted with HBr to form the compound [ka] and converting CPD-25 to CPD-04.

[0091] In some embodiments of the method for preparing compound CPD-04, the method comprises reacting compound CPD-25 with compound [ka] and a base to form the compound [ka] The method further includes forming a

[0092] In some embodiments, the base used to form CPD-26 is selected from the group consisting of K2CO3 and Cs2CO3. In some embodiments, the base used to form CPD-26 is K2CO3. In some embodiments, the base used to form CPD-26 is Cs2CO3. In some embodiments of the method for preparing compound CPD-04, the method includes contacting compound CPD-26 with CO in the presence of a palladium catalyst, an amine base, and methanol to prepare compound CPD-04. [ka] The method further includes forming a

[0093] In some embodiments of the method for preparing compound CPD-26, the palladium catalyst is Pd(dppf)Cl 2 ·DCM. In some embodiments of the process for preparing compound CPD-26, the amine base is triethylamine. Scheme 9 shows an alternative method for synthesizing CPD-17 starting from CPD-26. The CPD-26 so utilized can be derived from any of the embodiments described herein that produce CPD-26. The CPD-17 so generated can be used in any of the embodiments disclosed herein that utilize CPD-17.

[0094] Scheme 9 [ka]

[0095] According to Scheme 9, some embodiments of the present application provide a method for preparing compound CPD-17, comprising contacting compound CPD-26 with butyl vinyl ether in the presence of a palladium catalyst, a phosphorus reagent, and a base to obtain compound CPD-17. [ka] The method includes forming a

[0096] In some embodiments of forming CPD-27, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-27, the phosphorus reagent is 1,1'-ferrocenediyl-bis(diphenylphosphine) (dppf). In some embodiments forming CPD-27, the base is iPr2NEt. In some embodiments of the method for preparing CPD-17, the method includes contacting compound CPD-27 with an acid to produce compound CPD-27. [ka] The method further includes forming a

[0097] In some embodiments of forming CPD-17, the acid is HCl. Scheme 10 shows an alternative method for synthesizing CPD-17 starting from CPD-26. The CPD-26 so utilized can be derived from any of the embodiments described herein that produce CPD-26. The CPD-17 so generated can be used in any of the embodiments disclosed herein that utilize CPD-17.

[0098] Scheme 10 [ka]

[0099] According to Scheme 10, some embodiments of the present application provide a method for preparing compound CPD-17, comprising: (a) compound [ka] with hydroxyethyl vinyl ether in the presence of a palladium catalyst, a phosphorus reagent, and a base to form a mixture; (b) contacting the mixture of (a) with an acid to form the compound [ka] forming a The method includes the method comprising:

[0100] In some embodiments of forming CPD-17, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-17, the phosphorus reagent is 1,3-bis(diphenylphosphino)propane (dppp). In some embodiments forming CPD-17, the base is iPr2NEt. In some embodiments of forming CPD-17, the acid is HCl. Scheme 11 shows an alternative method for synthesizing CPD-18 starting from CPD-28. The CPD-28 thus utilized can be derived from any of the embodiments described herein that produce CPD-28. The CPD-18 thus generated can be used in any of the embodiments disclosed herein that utilize CPD-18.

[0101] Scheme 11 [ka]

[0102] According to Scheme 11, some embodiments of the present application provide a method for preparing compound CPD-18, comprising: (a) compound [ka] with a vinyltin reagent in the presence of a palladium catalyst to form a mixture; (b) contacting the mixture of (a) with an acid to form the compound [ka] forming a The method includes the method comprising:

[0103] In some embodiments of forming CPD-18, the vinyltin reagent is [ka] is. In some embodiments of forming CPD-18, the palladium catalyst is Pd(dppf)Cl 2 . In some embodiments of forming CPD-18, the acid is HCl. Scheme 12 shows an alternative method for synthesizing CPD-18 starting from CPD-29. The CPD-29 so utilized can be derived from any of the embodiments described herein that produce CPD-29. The CPD-18 so generated can be used in any of the embodiments disclosed herein that utilize CPD-18.

[0104] Scheme 12 [ka]

[0105] According to Scheme 12, some embodiments of the present application provide a method for preparing compound CPD-18, comprising contacting compound CPD-28 with butyl vinyl ether in the presence of a palladium catalyst, a phosphorus reagent, and a base to obtain compound CPD-28. [ka] The method includes forming a

[0106] In some embodiments of forming CPD-18, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-18, the phosphorus reagent is 1,1'-ferrocenediyl-bis(diphenylphosphine) (dppf). In some embodiments forming CPD-18, the base is iPr2NEt.

[0107] In some embodiments of the method for preparing CPD-18, the method comprises contacting compound CPD-29 with an acid to produce compound CPD-18. [ka] The method further includes forming a In some embodiments of forming CPD-18, the acid is HCl. Scheme 13 shows an alternative method for synthesizing CPD-18 starting from CPD-30. The CPD-30 so utilized can be derived from any of the embodiments described herein that produce CPD-30. The CPD-18 so generated can be used in any of the embodiments disclosed herein that utilize CPD-18.

[0108] Scheme 13 [ka]

[0109] According to Scheme 13, some embodiments of the present application provide a method for preparing compound CPD-18, comprising contacting compound CPD-30 with butyl vinyl ether in the presence of a palladium catalyst, a phosphorus reagent, and a base to obtain compound CPD-30. [ka] The method includes forming a

[0110] In some embodiments of forming CPD-18, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-18, the phosphorus reagent is 1,1'-ferrocenediyl-bis(diphenylphosphine) (dppf). In some embodiments forming CPD-18, the base is iPr2NEt. In some embodiments of the method for preparing CPD-18, the method comprises contacting compound CPD-29 with an acid to produce compound CPD-18. [ka] The method further includes forming a

[0111] In some embodiments of forming CPD-18, the acid is HCl. Scheme 14 shows an alternative method for synthesizing CPD-18 starting from CPD-30. The CPD-30 so utilized can be derived from any of the embodiments described herein that produce CPD-30. The CPD-18 so generated can be used in any of the embodiments disclosed herein that utilize CPD-18.

[0112] Scheme 14 [ka]

[0113] According to Scheme 14, some embodiments of the present application provide a method for preparing compound CPD-18, comprising: (a) compound [ka] with hydroxyethyl vinyl ether in the presence of a palladium catalyst, a phosphorus reagent, and a base to form a mixture; (b) contacting the mixture of (a) with an acid to form the compound [ka] forming a The method includes the method comprising:

[0114] In some embodiments of forming CPD-17, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-17, the phosphorus reagent is 1,3-bis(diphenylphosphino)propane (dppp). In some embodiments forming CPD-17, the base is iPr2NEt. In some embodiments of forming CPD-17, the acid is HCl. Scheme 15 shows an alternative method for synthesizing CPD-18 starting from CPD-28. The CPD-28 so utilized can be derived from any of the embodiments described herein that produce CPD-28. The CPD-18 so generated can be used in any of the embodiments disclosed herein that utilize CPD-18.

[0115] Scheme 15 [ka]

[0116] According to Scheme 15, some embodiments of the present application provide a method for preparing compound CPD-18, comprising: (a) compound [ka] with a vinyltin reagent in the presence of a palladium catalyst to form a mixture; (b) contacting the mixture of (a) with an acid to form the compound [ka] forming a The method includes the method comprising:

[0117] In some embodiments of forming CPD-18, the vinyltin reagent is [ka] is. In some embodiments of forming CPD-18, the palladium catalyst is Pd(dppf)Cl 2 . In some embodiments of forming CPD-18, the acid is HCl.

[0118] Scheme 16 shows an alternative method for synthesizing CPD-05 starting from CPD-28. The CPD-28 so utilized can be derived from any of the embodiments described herein that produce CPD-28. CPD-05 so generated can be used in any of the embodiments disclosed herein that utilize CPD-05.

[0119] Scheme 16 [ka]

[0120] According to Scheme 16, some embodiments of the present application provide a method for preparing compound CPD-05, comprising contacting compound CPD-28 with CO in the presence of a palladium catalyst, an amine base, and methanol to produce compound CPD-05. [ka] The method includes forming a

[0121] In some embodiments of forming CPD-05, the palladium catalyst is Pd(dppf)Cl 2 . In some embodiments of forming CPD-05, the amine base is triethylamine. Scheme 17 shows an alternative method for synthesizing CPD-05 starting from CPD-30. The CPD-30 so utilized can be derived from any of the embodiments described herein that produce CPD-30. CPD-05 so generated can be used in any of the embodiments disclosed herein that utilize CPD-05.

[0122] Scheme 17 [ka]

[0123] According to Scheme 17, some embodiments of the present application provide a method for preparing compound CPD-05, comprising contacting compound CPD-30 with CO in the presence of a palladium catalyst, a phosphorus reagent, an amine base, and methanol to obtain compound CPD-05. [ka] The method includes forming a

[0124] In some embodiments of forming CPD-05, the palladium catalyst is Pd(OAc) 2 . In some embodiments to form CPD-05, the phosphorus reagent is 1,1'-ferrocenediyl-bis(diphenylphosphine) (dppf). In some embodiments of forming CPD-05, the amine base is triethylamine. Scheme 18 shows an alternative method for synthesizing CPD-16 starting from CPD-28. The CPD-28 so utilized can be derived from any of the embodiments described herein that produce CPD-28. The CPD-16 so generated can be used in any of the embodiments disclosed herein that utilize CPD-16.

[0125] Scheme 18 [ka]

[0126] According to Scheme 18, some embodiments of the present application provide a method for preparing compound CPD-16, comprising contacting compound CPD-28 with MeNH(OMe) HCl in the presence of a palladium catalyst, a phosphorus reagent, CO, and a base to obtain compound CPD-28. [ka] The method includes forming a In some embodiments of forming CPD-16, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-16, the phosphorus reagent is Xantphos. In some embodiments of forming CPD-16, the base is K3PO4. Scheme 19 shows an alternative method for synthesizing CPD-16 starting from CPD-30. The CPD-30 so utilized can be derived from any of the embodiments described herein that produce CPD-30. The CPD-16 so generated can be used in any of the embodiments disclosed herein that utilize CPD-16.

[0127] Scheme 19 [ka]

[0128] According to Scheme 19, some embodiments of the present application provide a method for preparing compound CPD-16, comprising contacting compound CPD-30 with MeNH(OMe) HCl in the presence of a palladium catalyst, a phosphorus reagent, CO, and a base to obtain compound CPD-30. [ka] The method includes forming a In some embodiments of forming CPD-16, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-16, the phosphorus reagent is Xantphos. In some embodiments of forming CPD-16, the base is K3PO4. Scheme 20 shows an alternative method for synthesizing CPD-11 starting from CPD-26. The CPD-26 so utilized can be derived from any of the embodiments described herein that produce CPD-26. The CPD-11 so generated can be used in any of the embodiments disclosed herein that utilize CPD-11.

[0129] Scheme 20 [ka]

[0130] According to Scheme 20, some embodiments of the present application provide a method for preparing compound CPD-16, comprising: (a) contacting compound CPD-26 with CO in the presence of a palladium catalyst, an amine base, a phosphorus reagent, and MeOH / HO to form a mixture; (b) contacting the mixture of (a) with a base to form the compound [ka] forming a The method includes the method comprising:

[0131] In some embodiments of forming CPD-11, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-11, the amine base is triethylamine. In some embodiments of forming CPD-11, the phosphorus reagent is 1,1'-ferrocenediyl-bis(diphenylphosphine) (dppf). In some embodiments of forming CPD-11, the base is NaOH. Scheme 21 shows an alternative method for synthesizing CPD-06 starting from CPD-28. The CPD-28 so utilized can be derived from any of the embodiments described herein that produce CPD-28. CPD-06 so generated can be used in any of the embodiments disclosed herein that utilize CPD-06.

[0132] Scheme 21 [ka]

[0133] According to Scheme 21, some embodiments of the present application provide a method for preparing compound CPD-06, comprising contacting compound CPD-28 with CO in the presence of a palladium catalyst, a base, and a solvent mixture to obtain compound CPD-06. [ka] The method includes forming a

[0134] In some embodiments of forming CPD-06, the palladium catalyst is Pd(dppf)Cl 2 . In some embodiments of forming CPD-06, the base is Na2CO3. In some embodiments of forming CPD-06, the base is K2CO3. In some embodiments of forming CPD-06, the base is Li2CO3. In some embodiments of forming CPD-06, forming CPD-06 further comprises contacting CPD-28 with triethylamine. In some embodiments of forming CPD-06, the solvent mixture is MeOH / H2O. In some embodiments of forming CPD-06, the solvent mixture is acetonitrile / H2O. Scheme 22 shows an alternative method for synthesizing CPD-06 starting from CPD-30. The CPD-30 so utilized can be derived from any of the embodiments described herein that produce CPD-30. CPD-06 so generated can be used in any of the embodiments disclosed herein that utilize CPD-06.

[0135] Scheme 22 [ka]

[0136] According to Scheme 22, some embodiments of the present application provide a method for preparing compound CPD-06, comprising contacting compound CPD-30 with CO in the presence of a palladium catalyst, an amine base, a phosphorus reagent, a base, and DMF to obtain compound CPD-06. [ka] The method includes forming a

[0137] In some embodiments of forming CPD-06, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-06, the amine base is triethylamine. In some embodiments to form CPD-06, the phosphorus reagent is 1,1'-ferrocenediyl-bis(diphenylphosphine) (dppf). In some embodiments of forming CPD-06, the base is K2CO3. Scheme 23 shows an alternative method for synthesizing CPD-06 starting from CPD-11. The CPD-11 so utilized can be derived from any of the embodiments described herein that produce CPD-11. The CPD-06 so generated can be used in any of the embodiments disclosed herein that utilize CPD-06.

[0138] Scheme 23 [ka]

[0139] According to Scheme 23, some embodiments of the present application provide a method for preparing compound CPD-06, comprising contacting compound CPD-11 with a chlorinating reagent to obtain compound CPD-06. [ka] The method includes forming a In some embodiments of forming CPD-06, the chlorinating reagent is N-chlorosuccinimide. In some embodiments, the formation of CPD-06 further comprises contacting CPD-11 with dichloroacetic acid. Scheme 24 shows an alternative method for synthesizing CPD-15 starting from CPD-26. The CPD-26 thus utilized can be derived from any of the embodiments described herein that produce CPD-26. The CPD-15 thus produced can be used in any of the embodiments disclosed herein that utilize CPD-15.

[0140] Scheme 24 [ka] According to Scheme 24, some embodiments of the present application provide a method for preparing compound CPD-15, comprising contacting compound CPD-26 with MeNH(OMe) HCl in the presence of a palladium catalyst, a phosphorus reagent, CO, and a base to obtain compound CPD-26. [ka] The method includes forming a

[0141] In some embodiments of forming CPD-15, the palladium catalyst is Pd(OAc) 2 . In some embodiments of forming CPD-15, the phosphorus reagent is Xantphos. In some embodiments of forming CPD-15, the base is K3PO4. Scheme 25 shows an alternative method for synthesizing CPD-30 starting from CPD-26. The CPD-26 so utilized can be derived from any of the embodiments described herein that produce CPD-26. The CPD-30 so generated can be used in any of the embodiments disclosed herein that utilize CPD-30.

[0142] Scheme 25 [ka]

[0143] According to Scheme 25, some embodiments of the present application provide a method for preparing compound CPD-30, comprising contacting compound CPD-26 with a chlorinating reagent to give compound CPD-30. [ka] The method includes forming a

[0144] In some embodiments of forming CPD-30, the chlorinating reagent is N-chlorosuccinimide. In some embodiments, the formation of CPD-30 further comprises contacting CPD-26 with dichloroacetic acid. Scheme 26 shows an alternative method for synthesizing CPD-30 starting from CPD-31. The CPD-31 so utilized can be derived from any of the embodiments described herein that produce CPD-31. The CPD-30 so generated can be used in any of the embodiments disclosed herein that utilize CPD-30.

[0145] Scheme 26 [ka]

[0146] According to Scheme 26, some embodiments of the present application provide a method for preparing compound CPD-30, comprising reacting compound CPD-31 with compound [ka] and a base to form the compound [ka] The method includes forming a

[0147] In some embodiments, the base used to form CPD-30 is selected from the group consisting of K2CO3 and Cs2CO3. In some embodiments, the base used to form CPD-30 is K2CO3. In some embodiments, the base used to form CPD-30 is Cs2CO3. Scheme 27 shows an alternative method for synthesizing CPD-31 starting from CPD-25. The CPD-25 so utilized can be derived from any of the embodiments described herein that produce CPD-25. The CPD-31 so generated can be used in any of the embodiments disclosed herein that utilize CPD-31.

[0148] Scheme 27 [ka]

[0149] According to Scheme 27, some embodiments of the present application provide a method for preparing compound CPD-31, comprising contacting compound CPD-25 with a chlorinating reagent to obtain compound CPD-31. [ka] The method includes forming a In some embodiments of forming CPD-31, the chlorinating reagent is N-chlorosuccinimide. In some embodiments, the formation of CPD-31 further comprises contacting CPD-25 with dichloroacetic acid. Scheme 28 shows an alternative method for synthesizing CPD-28 starting from CPD-03. The CPD-03 so utilized can be derived from any of the embodiments described herein that produce CPD-03. CPD-28 so generated can be used in any of the embodiments disclosed herein that utilize CPD-28.

[0150] Scheme 28 [ka]

[0151] According to Scheme 28, some embodiments of the present application provide a method for preparing compound CPD-28, comprising contacting compound CPD-03 with a chlorinating reagent to give compound CPD-03. [ka] The method includes forming a In some embodiments of forming CPD-28, the chlorinating reagent is N-chlorosuccinimide. In some embodiments, the formation of CPD-28 further comprises contacting CPD-03 with dichloroacetic acid.

[0152] Some embodiments of the present application are [ka] 1. A method for preparing TAUT-01, comprising: compound [ka] in the presence of dimethylacetamide (DMAc) [ka] to form compound TAUT-01. The method is described, comprising:

[0153] Some embodiments provide a method for obtaining a single or enriched atropisomer of CPD-02, comprising subjecting CPD-02 to chromatographic separation: [ka] The present invention is directed to the above method, comprising the step of obtaining:

[0154] In some embodiments to obtain a single or enriched atropisomer of CPD-02, the chromatographic separation comprises simulated moving bed (SMB) chromatography with a chiral stationary phase and a mobile phase. In some embodiments for obtaining a single or enriched atropisomer of CPD-02, the chiral stationary phase is selected from the group consisting of Chiralpak® AD, Chiralpak® AS, Chiralpak® AY, Chiralpak® AZ, Chiralpak® OD, Chiralpak® OZ, Chiralpak® IA, Chiralpak® IB-N, Chiralpak® IC, Chiralpak® ID, Chiralpak® IE, Chiralpak® IF, Chiralpak® IG, and Chiralpak® IH.

[0155] In some embodiments to obtain single or enriched atropisomers of CPD-02, the chiral stationary phase is Chiralpak® IB-N. In some embodiments to obtain a single or enriched atropisomer of CPD-02, the mobile phase is selected from the group consisting of acetonitrile, methanol, acetonitrile and methanol, n-heptane and ethanol, n-heptane and dichloromethane, n-heptane and ethyl acetate, dichloromethane and methanol, and dichloromethane and acetonitrile. In some embodiments to obtain a single or enriched atropisomer of CPD-02, the mobile phase is dichloromethane and acetonitrile.

[0156] Some embodiments provide a method for obtaining a single or enriched atropisomer of CPD-03, comprising subjecting CPD-03 to chromatographic separation: [ka] The present invention is directed to the above method, comprising the step of obtaining: In some embodiments to obtain a single or enriched atropisomer of CPD-03, the chromatographic separation comprises simulated moving bed (SMB) chromatography with a chiral stationary phase and a mobile phase.

[0157] In some embodiments for obtaining a single or enriched atropisomer of CPD-03, the chiral stationary phase is selected from the group consisting of Chiralpak® AD, Chiralpak® AS, Chiralpak® AY, Chiralpak® AZ, Chiralpak® OD, Chiralpak® OZ, Chiralpak® IA, Chiralpak® IB-N, Chiralpak® IC, Chiralpak® ID, Chiralpak® IE, Chiralpak® IF, Chiralpak® IG, and Chiralpak® IH. In some embodiments to obtain single or enriched atropisomers of CPD-03, the chiral stationary phase is Chiralpak® IB-N.

[0158] In some embodiments to obtain a single or enriched atropisomer of CPD-03, the mobile phase is selected from the group consisting of acetonitrile, methanol, acetonitrile and methanol, n-heptane and ethanol, n-heptane and dichloromethane, n-heptane and ethyl acetate, dichloromethane and methanol, and dichloromethane and acetonitrile. In some embodiments to obtain a single or enriched atropisomer of CPD-03, the mobile phase is dichloromethane and acetonitrile.

[0159] Some embodiments provide a method for obtaining a single or enriched atropisomer of CPD-20, comprising subjecting CPD-20 to chromatographic separation: [ka] The present invention is directed to the above method, comprising the step of obtaining: In some embodiments to obtain a single or enriched atropisomer of CPD-20, the chromatographic separation comprises simulated moving bed (SMB) chromatography with a chiral stationary phase and a mobile phase.

[0160] In some embodiments for obtaining a single or enriched atropisomer of CPD-20, the chiral stationary phase is selected from the group consisting of Chiralpak® AD, Chiralpak® AS, Chiralpak® AY, Chiralpak® AZ, Chiralpak® OD, Chiralpak® OZ, Chiralpak® IA, Chiralpak® IB-N, Chiralpak® IC, Chiralpak® ID, Chiralpak® IE, Chiralpak® IF, Chiralpak® IG, and Chiralpak® IH. In some embodiments to obtain single or enriched atropisomers of CPD-20, the chiral stationary phase is Chiralpak® IB-N.

[0161] In some embodiments to obtain a single or enriched atropisomer of CPD-20, the mobile phase is selected from the group consisting of acetonitrile, methanol, acetonitrile and methanol, n-heptane and ethanol, n-heptane and dichloromethane, n-heptane and ethyl acetate, dichloromethane and methanol, and dichloromethane and acetonitrile. In some embodiments to obtain a single or enriched atropisomer of CPD-20, the mobile phase is dichloromethane and acetonitrile.

[0162] In any of the above, when the mobile phase is in the form of a mixture, the mixture can be in a volume ratio of about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 7:3, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 3:7, or any ratio intermediate therebetween.

[0163] In some embodiments of the present application, the salts disclosed herein may be co-crystals. Some embodiments of the present application include: [ka] [ka] or a salt thereof, or a co-crystal thereof.

[0164] Experimental section The compounds of the present invention can be prepared using the methods exemplified in the experimental procedures detailed below, but are not limited to these methods. The starting materials used to prepare the compounds of the present invention are commercially available or can be prepared using routine methods known in the art. Solvents and reagents whose synthetic preparations are not described below can be purchased from Sigma-Aldrich or Fisher Scientific. Representative procedures for the preparation of compounds of the present disclosure are outlined below.

[0165] Example 1: General split screening procedure Stock solutions of the racemates were prepared in pure MeOH or in a mixture of MeOH and CHCl3 in cases of low solubility. 15 μmol of the racemate was pipetted into a 96-tube plate. To these solutions, stock solutions of resolving agents (24 basic or 36 acidic resolving agents) were added. Each contained 15 μmol of resolving agent (or 7.5 μmol for half the equivalent amount of some double acids). The mobile solvent was evaporated in a circulating oven at 45°C for 2 days. The dried solids were treated with 0.5 mL of the eight solvent systems. The tubes were capped and heated to 70°C for 15 minutes with sonication. The resulting mixtures were allowed to cool to room temperature over 2-3 days. At least one and a maximum of two samples per resolving agent were prepared. The suspensions were filtered, and the solids and filtrates were dissolved in 1.5 mL of MeOH, respectively, and analyzed by chiral HPLC or chiral UPC. Because chiral methods are incompatible with water, if the filtrate contained water, it was first concentrated to dryness at 50°C using a stream of N2, followed by the addition of MeOH. The optical purity of the solid and filtrate for a given experiment was used to determine the yield. The results of various resolving agents isolating CPD-07 are shown in Table 1, with entries A and B being further detailed in Examples 9 and 10. The results of various resolving agents isolating Formula P-(I).

[0166] The yield of precipitated material was calculated as follows:

number

[0167] [Table 1] JPEG2023553814000130.jpg105170

[0168] [Table 2] JPEG2023553814000132.jpg134164

[0169] Example 2: Preparation of 3-acetyl-2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-01) [ka] To a round-bottom flask equipped with a short-path distillation head equipped with a receiving flask were added 2-chloro-5-methylpyridin-4-amine (SM-01) (42.0 kg, 1.0 equiv.), 2,2,6-trimethyl-4H-1,3-dioxin-4-one (SM-02) (3.7 equiv.), and DMAc (5.0 vol.). The reaction mass was slowly warmed to 115-120°C and maintained at that temperature for 4-6 hours. (Note: Acetone was collected in the receiving flask during this procedure.) The reaction was monitored by TLC and HPLC. After completion of the reaction, the mass was cooled to 50-60°C. Water (15.0 vol.) was slowly added to the reaction mass at 50-60°C. The mass was then cooled first to 25-30°C and then to 5-10°C. After stirring for 1-2 hours, the solid was filtered and washed with cold water (15.0 vol.). The solid was dried in a hot air oven to give 79.5 kg (yield: 92.3%) of 3-acetyl-2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one with an HPLC purity of 96.45%. 1 H-NMR (400 MHz, DMSO-d6): δ ppm 15.74 (s, 1H), 8.52 (s, 1H), 7.67 (s, 1H), 6.25 (s, 1H), 2.55 (s, 3H), 2.02 (s, 3H), 1.94 (s, 3H). MS (ES) m / z 293.62 (M+H).

[0170] Example 3: Preparation of 2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-02) [ka] To a round-bottom flask was added 3-acetyl-2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-01, Example 2) (65 kg, 1.0 equiv.), water (12.0 vol.), and IPA.HCl (20-25% solution) (3.5 vol.) at 25-30°C. The reaction mass was heated to 80-85°C and maintained at this temperature for 14-15 hours. The reaction was monitored by TLC. After completion of the reaction, the reaction mass was cooled to 5-10°C and stirred for 2-3 hours. The solid was filtered, washed with cold water, and dried for 1-2 hours. The material was then dried in an oven at 50-55°C to give 63.3 kg (72.3% yield) of 2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one with an HPLC purity of 83.7%. 1 H-NMR (400 MHz, DMSO-d6): δ ppm 10.8 (br s, 1H), 8.47 (s, 1H), 7.55 (s, 1H), 5.97-5.96 (m, 1H), 5.57 (d, J = 2.4 Hz, 1H), 1.96 (s, 3H), 1.83 (s, 3H). MS (ES) m / z 251.52 (M+H).

[0171] Example 4: Preparation of 2-chloromethyl-3,5-difluoro-pyridine (INT-01) [ka]

[0172] Step A: Preparation of 3,5-difluoro-pyridine-2-carboxylic acid ethyl ester [ka] To a cooled (using an ice-water bath) suspension of 3,5-difluoro-pyridine-2-carboxylic acid (2.0 g, 12.6 mmol) in ethanol (5 mL) was added thionyl chloride (2 mL) dropwise. The solution was then heated to 60° C. for 3 hours. The reaction was cooled to ambient temperature and concentrated in vacuo to give the ethyl ester hydrochloride salt as a yellow oil (2.5 g).

[0173] Step B: Preparation of (3,5-difluoro-pyridin-2-yl)-methanol [ka] To a cooled (using an ice-water bath) solution of 3,5-difluoro-pyridine-2-carboxylic acid ethyl ester (2.5 g, 12.6 mmol) from Part A in ethanol (10 mL) was added sodium borohydride (1.43 g, 37.8 mmol) in small portions. The solution was stirred at 0°C for 30 minutes and then at ambient temperature for 2 hours. The reaction mixture was cooled to 0°C, and saturated ammonium chloride was added dropwise. The solvent was removed in vacuo, and the resulting residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated ammonium chloride, water, and brine and dried over magnesium sulfate. The slurry was filtered and concentrated to give the alcohol as a yellow oil (1.8 g). MS (ES) m / e 146 (M+H).

[0174] Step C: Preparation of 2-chloromethyl-3,5-difluoro-pyridine [ka] To a solution of (3,5-difluoro-pyridin-2-yl)-methanol (1.8 g, 12.3 mmol) from Part B in dichloromethane (20 mL) was added three drops of N,N-dimethylformamide and cooled using an ice-water bath. Thionyl chloride (2 mL) was added dropwise, and the solution was stirred at ambient temperature for 1 hour. The solution was concentrated in vacuo to give the chloro compound (1.75 g) as a light brown liquid.

[0175] Example 5 Preparation of 2'-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-03) [ka] To a stirred solution of 2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-02, Example 3) (200.0 g, 1.0 equiv.) in DMF (4 vol.) was added K2CO3 (1.5 equiv.) at room temperature. It was stirred for 10-15 min, and then 2-(chloromethyl)-3,5-difluoro-pyridine (INT-01, Example 4) (1.2 equiv.) in DMF (1 vol.) was added slowly at 25-35°C. The reaction mass was stirred at 25-35°C for 16-18 h. The progress of the reaction was monitored by TLC and IPC-HPLC. After the reaction was complete (<5.0% (NMT) a / a), ice-cold water (20 vol.) was charged. The mixture was stirred for 1 h and then extracted with EtOAc (3 x 10 vol.). The combined EtOAc layers were washed with water (1×5 volumes) and brine solution (1×5 volumes), then dried over anhydrous sodium sulfate. The EtOAc layer was evaporated under reduced pressure at 45–50°C. MTBE (1–2 volumes) was added, and the mixed solvents were co-distilled. Additional MTBE (3 volumes) was added at 25–35°C to precipitate a solid. After filtration, the wet solid was dried under reduced pressure at 45–50°C to give 244 g of 2′-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2H-[1,4′-bipyridin]-2-one with an HPLC purity of 96.45% (yield: 80.9%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.58 (d, 1H, J = 2.4 Hz); 8.49 (s, 1H); 8.03-8.10 (m, 1H), 7.60 (s, 1H), 6.11-6.14 (m, 1H), 6.02 (d, 1H, J = 2.4 Hz), 5.24 (d, 2H, J = 1.6 Hz), 1.98 (s, 3H), 1.85 (s, 3 H), MS (ES) m / z 378.19 (M+H).

[0176] Example 6: Preparation of methyl 4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxylate (CPD-04) [ka] To a stirred suspension of 2'-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-03, Example 5) (100.0 g, 1.0 equiv.) in methanol (8 volumes) was added triethylamine (TEA) (3.0 equiv.). The reaction was purged with argon gas for 30 minutes. The reaction mass was then transferred to an autoclave under argon atmosphere, and Pd(dppf)Cl2 (0.05 equiv.) was added. The reactor was pressurized with CO gas (15 PSI (1 Kg)). The pressure was released, and the reactor was repressurized with CO pressure (75 PSI (5 Kg)). The temperature was increased to 95-100 °C and maintained for 16 hours. The reaction progress was monitored by TLC. After completion of the reaction, the reaction mass was cooled to 25-35°C. The pressure was released and the reactor was purged with nitrogen. The contents of the reactor were filtered through a bed of Celite. The filtrate was distilled under reduced pressure below 45°C and co-distilled with EtOAc (1-2 volumes). A crude solid was obtained, which was diluted with EtOAc (5 volumes) and stirred at 25-35°C for 1-2 hours. The mixture was filtered to give 85 g of methyl 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate with an HPLC purity of 99.37% (yield: 80%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.78 (s, 1H), 8.59 (d, 1H, J = 2.4 Hz), 8.04-8.11 (m, 1H), 7.90 (s, 1H), 6.12-6.15 (m, 1H), 6.03 (d, MS (ES) m / z 402.44 (M+H).

[0177] Example 7: Preparation of methyl 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxylate (CPD-05) [ka] To a stirred suspension of methyl 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (CPD-04, Example 6) (100.0 g, 1.0 equiv.) in IPA (15.0 volumes) was added dichloroacetic acid (0.25 equiv.) at 25-35°C. The temperature was slowly raised to 45-50°C, and N-chlorosuccinimide (0.95 equiv.) was added. The temperature was then raised to 60-65°C and maintained for 1 hour. The progress of the reaction was monitored by TLC. After completion of the reaction, the heat was turned off and the reaction mass was allowed to cool to 25-35°C and then to 0-5°C. The solid was filtered and washed with IPA. The wet solid was dried at 45-50°C to give 70 g of methyl 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate with an HPLC purity of 96.46% (yield: 64.5%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.82 (s, 1H), 8.60 (d, 1H, J = 2.4 Hz), 8.07-8.13 (m, 1H), 8.03 (s, 1H), 6.79 (d, 1H, J = 0.4 Hz), 5.47 (d, 2H, J = 1.2 Hz), 3.89 (s, 3H), 2.08 (s, 3H), 1.92 (s, 3H), MS (ES) m / z 436.36 (M+H).

[0178] Example 8 Preparation of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxylic acid (CPD-06) [ka] To a stirred solution of methyl 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (CPD-05, Example 7) (34 g, 1.0 equiv.) in THF (5 vol.) was added LiOH·HO (3.0 equiv.) in water (5 vol.) at 25-35°C. The mixture was then stirred for 2-4 h. After completion of the reaction, EtOAc (5.0 vol.) was added. After stirring for 10-15 min, the aqueous and organic layers were separated. The pH of the aqueous layer was adjusted to 3-5 using dilute HCl (4 M solution) at 25-35°C. The solid was filtered and washed with n-heptane (2-3 vol.). The resulting wet solid was dried at 45-50 °C for 3-4 hours to give 23.0 g of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid with an HPLC purity of 97.93% and chiral HPLC purity of isomer 1:isomer 2 (48.75%:51.25%) (yield: 70.0%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 13.35 (br s, 1H), 8.80 (s, 1H), 8.60 (d, 1H, J = 2.4 Hz), 8.01-8.13 (m, 1H), 7.97 (s, 1H), 6.79 (s, 1H), 5.47 (d, 2H, J = 1.6 Hz), 2.08 (s, 3 H), 1.92 (s, 3 H), MS (ES) m / z 422.36 (M+H).

[0179] Example 9 Preparation of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxylic acid (CPD-07) via chiral separation using (S)-1-(naphthalen-2-yl)ethan-1-amine [ka]

[0180] Step 1: Synthesis of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (A salt of isomer 1) [ka]

[0181] Step 1: To a stirred suspension of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-06, Example 8, Isomer 1:Isomer 2, 48.75%:51.25%) (10 g, 1.0 equiv.) in ethanol (200 mL, 20 vol.) (250 mL round-bottom flask) was added 0.9 equiv. of (S)-1-(naphthalen-2-yl)ethan-1-amine at 60-65 °C (Note: A clear solution was observed after the addition of (S)-1-(naphthalen-2-yl)ethan-1-amine). Stirring was then continued at 60-65 °C for 1-2 hours. The stirred solution was allowed to cool to 25-35 °C for 24 hours. The solid was filtered to give 15 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethane-1-aminium (A salt of Isomer 1) in improved HPLC chiral purity (Isomer 1:Isomer 2, 55.36%:44.64%). 1H-NMR (400 MHz, DMSO-d6): δ ppm 8.58-8.62 (m, 2H), 8.58-8.62 (m, 2H), 8.04-8.14 (m, 1H), 7.82-8.02 (m, 4H), 7.72 (s, 1H), 7.62-7.70 (m, 1H), 7.45-7.57 (m, 2H), 6.11-6.14 (m, 1H), 6.77 (s, 1H), 5.45 (d, 2H, J = 10.8 Hz), 4.43-4.55 (m, 1H), 2.04 (s, 3 H), 2.00 (s, 3H), 1.45-1.60 (m, 3H); MS (ES) m / z 422 (M+H).

[0182] Step 2: First purification of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (A salt of isomer 1). Wet solid (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethane-1-aminium (A salt of isomer 1) (Example 9, Step 1, 15 g, isomer 1:isomer 2, 55.36%:44.64) in methanol (10 volumes) was heated with stirring to 60-65 °C for 1-2 hours to give a clear solution. Heating was then stopped and the solution was allowed to cool to 25-35 °C. The mixture was stirred for 24 hours and filtered. Thus, 11.5 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium were obtained with improved HPLC chiral purity (isomer 1:isomer 2, 83.06%:16.94%).

[0183] Step 3: Second purification of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (A salt of isomer 1). Wet solid (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethane-1-aminium (A salt of Isomer 1) (Example 9, Step 2, 11.5 g, Isomer 1:Isomer 2, 83.06%:16.94%) in methanol (10 volumes) was heated with stirring to 60-65 °C for 1-2 hours. The heat was then removed and the solution was allowed to cool to 25-35 °C. The mixture was stirred for 24 hours and then filtered. Thus, 8.9 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (A salt of isomer 1) was obtained with improved HPLC chiral purity (isomer 1:isomer 2, 92.48%:7.52%).

[0184] Step 4: Third purification of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethane-1-aminium (A salt of isomer 1). Wet solid (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethane-1-aminium (A salt of Isomer 1) (Example 9, Step 3, 8.9 g, Isomer 1:Isomer 2, 92.48%:7.52%) in methanol (10 volumes) was heated with stirring to 60-65 °C for 1-2 h. Heating was then stopped and the solution was allowed to cool to 25-35 °C. The mixture was stirred for 24 h and then filtered. Thus, 8.0 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (A salt of isomer 1) was obtained with improved HPLC chiral purity (isomer 1:isomer 2, 95.26%:4.74%).

[0185] Step 5: Fourth purification of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (A salt of isomer 1). Wet solid (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethane-1-aminium (A salt of Isomer 1) (Example 9, Step 4, 8.0 g, Isomer 1:Isomer 2, 95.26%:4.74%) in methanol (10 volumes) was heated with stirring to 60-65 °C for 1-2 h. Heating was then stopped and the solution was allowed to cool to 25-35 °C. The mixture was stirred for 24 h and then filtered. Thus, 6.0 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (A salt of isomer 1) was obtained with improved HPLC chiral purity (isomer 1:isomer 2, 98.29%:1.71%).

[0186] Step 6: Fifth purification of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (A salt of isomer 1). Wet solid (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethane-1-aminium (A salt of isomer 1) (Example 9, Step 5, 6.0 g, isomer 1:isomer 2, 98.29%:1.71) in methanol (10 volumes) was heated with stirring to 60-65 °C for 1-2 h. Heating was then stopped and the solution was allowed to cool to 25-35 °C. The mixture was stirred for 24 h and then filtered. Thus, 6.0 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (A salt of isomer 1) was obtained with improved HPLC chiral purity (isomer 1:isomer 2, 98.29%:4.74%).

[0187] Step 7: Synthesis of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-07) [ka] (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (Isomer 1 A salt) (Example 9, Step 6, 4.2 g, Isomer 1:Isomer 2, 98.29%:4.74%) was dissolved in water (42 mL, 10 vol) and made basic (pH ∼12) with 2N NaOH. It was extracted three times with EtOAc (42 mL, 10 vol). The EtOAc extract contained (S)-1-(naphthalen-2-yl)ethan-1-amine. The aqueous layer was made acidic (pH 2) with 2N HCl, causing a solid to precipitate. The solid was filtered and washed with n-heptane (2 volumes) to give chiral (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxylic acid (2.3 g, dried) in HPLC chiral purity (isomer 1, isomer 2, 99.86%:0.14%).

[0188] Example 10: Preparation of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-07) via chiral separation using (1S,2R)-2-amino-1,2-diphenylethan-1-ol [ka]

[0189] Step 1: Synthesis of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (B salt of isomer 1) [ka]

[0190] To a stirred suspension of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-06, Example 8) (5 g, 1.0 equiv.) in acetonitrile (100 mL, 20 vol.) (250 mL round-bottom flask) was added 1.0 equiv. of (1S,2R)-2-amino-1,2-diphenylethan-1-ol at 60-65 °C (Note: A clear solution was observed after the addition of (1S,2R)-2-amino-1,2-diphenylethan-1-ol). Stirring was continued at 60-65 °C for 1-2 hours. The stirred solution was allowed to cool to 25-35 °C for 24 hours. The solid was filtered to give 4 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate(1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (B salt of Isomer 1) in improved HPLC chiral purity (Isomer 1:Isomer 2, 58.98%:41.02%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.68 (s, 1H), 8.59 (d, 1H, J = 2.4 Hz), 8.05-8.14 (m, 1H), 7.45-7.57 (m, 2H), 7.81 (s, 1H), 7.08-7.25 (m, 11H), 6.77 (s, 1H), 5.47 (d, 2H, J = 1.6 Hz), 4.8-4.95 (m, 1H), 4.16-4.24 (m, 1H), 2.08 (s, 3 H), 2.06 (s, 3H), 1.91 (d, 3 H, J = 7.2 Hz); MS (ES) m / z 422.28 (M+H).

[0191] Step 2: First purification of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (B salt of isomer 1). Wet solid (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate(1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (B salt of Isomer 1) (Example 10, Step 1, 4 g, Isomer 1:Isomer 2, 58.98%:41.02%) in methanol (10 volumes) was heated with stirring to 60-65 °C for 1-2 hours to give a clear solution. Heating was then stopped and the solution was allowed to cool to 25-35 °C. The mixture was stirred for 24 hours and filtered. Thus, 3.1 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate(1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (B salt of isomer 1) was obtained with improved HPLC chiral purity (isomer 1:isomer 2, 75.72%:24.28%).

[0192] Step 3: Second purification of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (B salt of Isomer 1). Wet solid (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate(1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (B salt of Isomer 1) (Example 10, Step 2, 3.1 g, Isomer 1:Isomer 2, 75.72%:24.28%) in methanol (10 volumes) was heated with stirring to 60-65 °C for 1-2 hours to give a clear solution. Heating was then stopped and the solution was allowed to cool to 25-35 °C. The mixture was stirred for 24 hours and filtered. Thus, 2.0 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate(1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (B salt of isomer 1) was obtained with improved HPLC chiral purity (isomer 1:isomer 2, 81.27%:18.73%).

[0193] Step 4: Third purification of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (B salt of isomer 1). Wet solid (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (B salt of isomer 1) (step 3, 2 g, isomer 1:isomer 2, 81.27%:18.73%) in methanol (10 volumes) was heated to 60-65 °C with stirring for 1-2 h. Heating was then stopped and the solution was allowed to cool to 25-35 °C. The mixture was stirred for 24 h and then filtered. Thus, 0.5 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate(1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (B salt of isomer 1) was obtained with improved HPLC chiral purity (isomer 1:isomer 2, 99.19%:0.81%).

[0194] Step 5: Synthesis of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-07) [ka]

[0195] (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1R,2S)-2-hydroxy-1,2-diphenylethan-1-aminium (the B salt of isomer 1) (Step 4, 0.5 g, isomer 1:isomer 2, 99.19%:0.81%) was dissolved in water (5 mL, 10 vol) and made basic (pH ∼12) with 2N NaOH. It was extracted three times with EtOAc (5 mL, 10 vol). The EtOAc extract contained (1S,2R)-2-amino-1,2-diphenylethan-1-ol. The aqueous layer was acidified (pH 2) with 2N HCl to precipitate a solid. The solid was filtered and washed with n-heptane (2 volumes) to give chiral (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxylic acid (0.25 g, dried) in HPLC chiral purity (isomer 1:isomer 2, 99.19%:0.81%).

[0196] Example 11: Preparation of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid via chiral separation using (1R,2S)-2-amino-1,2-diphenylethan-1-ol (CPD-32) [ka]

[0197] Step 1: Synthesis of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2). [ka]

[0198] To a stirred suspension of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-06, Example 8) (5.0 g, 1.0 equiv.) in acetonitrile (100 mL, 20 vol.) (250 mL round-bottom flask) was added 1.0 equiv. of (1R,2S)-2-amino-1,2-diphenylethan-1-ol at 60-65 °C (Observation: A clear solution was observed after the addition of (1R,2S)-2-amino-1,2-diphenylethan-1-ol). Stirring was then continued at 60-65 °C for 1-2 hours. The stirred solution was allowed to cool to 25-35 °C for 24 hours. The solid was filtered to give 6.0 g of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyrid-ine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2) in improved HPLC chiral purity (isomer 1:isomer 2, 18.86%:81.14%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.68 (s. 1H), 8.59 (d, 1H, J = 2.4 Hz), 8.04- 8.12 (m, 1H), 7.81 (s, 1H), 7.16-7.29 (m, 9H), MS (ES) m / z 422 (M+H).

[0199] Step 2: First purification of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2). Wet solid (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2) (step 1, 6.0 g, isomer 1:isomer 2, 18.86%:81.14%) in methanol (10 volumes) was heated to 60-65 °C with stirring for 1-2 h to give a clear solution. Heating was then stopped and the solution was allowed to cool to 25-35 °C. The mixture was stirred for 24 h and filtered. Thus, 4.0 g of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2) was obtained with improved HPLC chiral purity (isomer 1:isomer 2, 15.487%:84.52%).

[0200] Step 3: Second purification of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2). Wet solid (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2) (Step 2, 4.0 g, isomer 1:isomer 2, 15.487%:84.52%) in methanol (10 volumes) was heated to 60-65 °C with stirring for 1-2 h to give a clear solution. Heating was then stopped and the solution was allowed to cool to 25-35 °C. The mixture was stirred for 24 h and filtered. Thus, 2.0 g of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2) was obtained with improved HPLC chiral purity (isomer 1:isomer 2, 12.567%:87.44%).

[0201] Step 4: Third purification of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2). Wet solid (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2) (step 3, 2.0 g, isomer 1:isomer 2, 12.567%:87.44) in methanol (10 volumes) was heated with stirring to 60-65 °C for 1-2 h. Then, heating was stopped and the solution was allowed to cool to 25-35 °C. The mixture was stirred for 24 h and then filtered. Thus, 1.5 g of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2) was obtained with improved HPLC chiral purity (isomer 1:isomer 2, 0.137%:99.87%).

[0202] Step 5: Synthesis of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid [ka]

[0203] (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (1S,2R)-2-hydroxy-1,2-diphenylethan-1-aminium (C salt of isomer 2) (Step 4, 1.5 g, isomer 1:isomer 2, 0.137%:99.87) was dissolved in water (5 mL, 10 vol) and made basic (pH ∼12) with 2N NaOH. It was extracted three times with EtOAc (5 mL, 10 vol). The EtOAc extract contained (1R,2S)-2-amino-1,2-diphenylethan-1-ol. The aqueous layer was acidified (pH 2) with 2N HCl to precipitate a solid. The solid was filtered and washed with n-heptane (2 volumes) to give chiral (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxylic acid (0.25 g, dried) in HPLC chiral purity (isomer 1:isomer 2, 0.137%:99.87%).

[0204] Example 12: Preparation of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (Formula P-(I)) [ka]

[0205] Step 1: Synthesis of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CPD-08) [ka]

[0206] To a stirred solution of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-07, Example 9, Step 7) (6.0 g, 1.0 equiv., Isomer I:Isomer 2, 99.86%:0.14%) in DMF (8 vol.), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC·HCl (1.0 equiv.)) was added at 0-5 °C and stirred for 5-10 min. TEA (1.0 equiv.) was added at 0-5 °C, and the mixture was stirred for 10-20 min. N,O-dimethylhydroxylamine hydrochloride (1.5 equiv.) was then added at 0-5 °C. The mixture was stirred for 1-2 h, and the reaction progress was monitored by TLC. After completion of the reaction, the reaction was allowed to cool to 25-35°C. Ice-cold water (20.0 vol) was added and stirring was continued for 30-45 min. The mixture was then extracted with EtOAc (3 x 10 vol). The combined EtOAc layers were washed with ice-cold water (10 vol) and dried over anhydrous sodium sulfate. After filtration, the EtOAc was completely evaporated, and MTBE (2 vol) was added and stirred for 1-2 h. The solid was filtered and dried below 45°C to give 5.0 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide with an HPLC purity of 99.0% and an HPLC chiral purity of 99.56% (isomer 1: isomer 2, 0.44%) (yield: 75%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.70 (s, 1H), 8.59 (d, 1H, J = 2.4 Hz), 8.04-8.12 (m, 1H), 7.63 (s, 1H), 6.79 (s, 1H), 5.47 (d, 2H, J = MS (ES) m / z 465.31 (M+ H).

[0207] Step 2: Synthesis of (P)-2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-09) [ka]

[0208] To a stirred solution of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5′,6-trimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxamide (CPD-08, Example 12, Step 1) (5.0 g, Isomer 1:Isomer 2 (99.56%:0.44%)) in dry THF (42 vol) was added MeMgBr (9.5 equiv; 2M (THF solution) was added slowly at 0-10°C. The temperature of the reaction mass was then raised to 0-5°C and maintained for 1 hour. The reaction mass was quenched with 15% aqueous ammonium chloride solution (10 vol) and extracted with EtOAc (2 x 10 vol). The combined EtOAc layers were evaporated completely to give a crude solid. The solid was dissolved in dichloromethane (DCM (1 vol)) and then precipitated by adding hexane (9 vol). The solid was filtered to give 3.0 g of (P)-2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one with an HPLC purity of 98.80% and an HPLC chiral purity of (Isomer 1:Isomer 2, 99.86%:0.14%) (Yield: 66%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.83 (s, 1H), 8.59 (d, 1H, J = 2.4 Hz), 8.05-8.14 (m, 1H), 7.89 (s, 1H), 6.79 (s, 1H), 5.47 (d, 2H, J = 1.6 Hz), 2.66 (s, 3H), 2.09 (s, 3H), 1.91 (s, 3H); MS (ES) m / z 420.08 (M+ H).

[0209] Step 3: Synthesis of (P)-(E)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(3-(dimethyl-amino)acryloyl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-10) [ka]

[0210] To a stirred solution of (P)-2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-09, Example 12, Step 2) (2.0 g, 1.0 equiv., Isomer 1:Isomer 2, 99.86%:0.14%), N,N-dimethylformamide dimethyl acetal (DMF-DMA (8.0 equiv.)) and DMF (1.0 vol.) were added at 25-35°C. The reaction mass was slowly heated to 50-55°C and maintained at that temperature for 24 hours. The progress of the reaction was monitored by TLC. After completion of the reaction, the heat was removed and the mixture was cooled to 25-35°C. Dichloromethane (DCM) (10.0 vol.) and water (10.0 vol.) were then added. The mixture was stirred for 10-15 minutes and the layers were separated. The aqueous layer was extracted with DCM (2 x 10 volumes). The combined DCM layers were washed with ice-cold water (2 x 10 volumes) and dried over anhydrous sodium sulfate. The DCM layer was concentrated below 35 °C to give a crude solid. EtOAc (2.0 volumes) was added, and the mixture was stirred at 25-35 °C for 1-2 hours. The solid was filtered to give 1.8 g of (P)-(E)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(3-(dimethylamino)acryloyl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one with HPLC 97.05% purity and HPLC chiral purity (isomer 1: isomer 2 (99.96%:0.04%)) (yield: 79.6%). 1H-NMR (400 MHz, DMSO-d6): δ ppm 8.71 (s, 1H), 8.60 (d, 1H, J = 2.4 Hz), 8.04-8.12 (m, 1H), 7.80-7.86 (m, 2H), 6.78 (s, 1H), 6.37 (d, MS (ES) m / z 475.36 (M+H).

[0211] Step 4: Synthesis of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (Formula P-(I)) [ka]

[0212] To a stirred solution of (P)-(E)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(3-(dimethyl-amino)acryloyl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-10, Example 12, Step 3) (5.4 g, 1.0 equiv., Isomer 1:Isomer 2, 99.96%:0.04%) in DMF (6.0 vol.) was added K2CO3 (2.5 equiv.). After stirring for 5-10 min at 25-35 °C, 2-hydroxy-2-methylpropionamidine HCl (INT-02) (3.0 equiv.) was added at 25-35 °C. The reaction mass was slowly warmed to 45-50 °C and stirred at that temperature for 7 h. The reaction progress was monitored by TLC / IPC HPLC. After the reaction was complete, it was cooled to 10-15 °C, diluted with water (20 volumes), and stirred for 1-2 hours at 10-15 °C. The solid was filtered and dried to give 5.0 g of crude (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one in HPLC chiral purity (isomer 1:isomer 2, 95%:5%).

[0213] Step 5: Purification of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (Formula P-(I)) [ka]

[0214] Crude (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxy-propan-2-yl)-pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (Formula P-(I), Example 12, Step 4) (5.0 g, 1.0 equiv., Isomer 1:Isomer 2, 95%:5%) in IPA (19.0 vol) was stirred at 72-75 °C for 1 h. Seed material (Formula P-(I), Example 12, Step 4) (0.25 g, 0.05 (w / w) fold, Seed Crystal's Assay 98.4%) was then added at 72-75 °C. Heating was turned off, and the mixture was allowed to cool to 25-35 °C. After stirring for 24 h, the solid was filtered. The solid was washed with IPA (2.0 vol) and dried at <40°C to give 4.4 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)-pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one with an HPLC purity of 99.52% and an HPLC chiral purity of (isomer 1:isomer 2, 99.65%:0.35%) (yield: 75%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.97 (d, 1H, J = 5.2 Hz), 8.86 (s, 1H), 8.69 (s, 1H), 8.61 (d, 1H, J = 2.4 Hz), 8.24 (d, 1H, J = 5.2 Hz), 8.06-8.14 (m, 1H), 6.84 (s, 1H), 5.49 (d, 2H, J = 1.2 Hz), 5.25 (s, 1H), 2.10 (s, 3H), 1.98 (s, 3H), 1.04 (s, 3 H), 1.03 (s, 3H); MS (ES) m / z 514.37 (M+ H).

[0215] Example 13 Preparation of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-20) via Sonogashira Coupling [ka]

[0216] Step 1: Synthesis of 4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(3-hydroxyprop-1-yn-1-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-21) [ka]

[0217] To a pre-cleaned round-bottom flask was added water (5 volumes, 200 mL) and 1,4-dioxane (5 volumes, 200 mL). The solvent was then degassed with argon for 10 minutes. 2'-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-03, Example 5) (40.0 g, 106 mmol, 1 equiv.), TPP (5.55 g, 21.2 mmol, 0.2 equiv.), TEA (73.8 mL, 530.0 mmol, 5 equiv.), CuI (1.0 g, 5.3 mmol, 0.05 equiv.), and 10% Pd / C (11.29 g, 5.3 mmol, 0.05 equiv.) were then added to the round-bottom flask. The mixture was degassed with argon for 10 minutes, and propargyl alcohol (24.7 mL, 424.4 mmol, 4 equiv.) was added to the reaction mixture. The mixture was stirred at room temperature for 10 minutes. The reaction mixture was then heated to 90° C. for 62 hours and monitored by LC-MS. Upon completion, the reaction mixture was cooled to room temperature, filtered, and washed with EtOAc. The filtrate was extracted with EtOAc and washed with brine solution. The organic layer was dried over Na2SO4 and concentrated under reduced pressure to give crude 4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(3-hydroxyprop-1-yn-1-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-21). The crude compound (CPD-21) was purified by silica gel (230-400 mesh) column chromatography eluting with 2-4% MeOH / DCM to give the desired 4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(3-hydroxyprop-1-yn-1-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-21) as a yellow solid (18.5 g, 44%) with 93% HPLC purity. 1H-NMR (300 MHz, CDCl3) δ ppm: 8.59 (s, 1H), 8.41 (d, J = 2.1 Hz, 1H), 7.29 (s, 1H), 7.22 (s, 1H), 6.03 (d, J = 2.4 Hz, 1H), 5.96 (m, 1H), 5.19 (d, J = 1.8 Hz, 2H), 4.50 (d, J = 6.0 Hz, 2H), 2.13 (s, 3H), and 1.85 (s, 3H). MS(ES), m / z = 398.79 (M+H).

[0218] Step 2: Synthesis of 3-(4-(4-((3,5-difluoropyridin-2-yl)methoxy)-6-methyl-2-oxopyridin-1(2H)-yl)-5-methylpyridin-2-yl)propioaldehyde (CPD-22) [ka]

[0219] A stirred solution of 4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(3-hydroxyprop-1-yn-1-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-21, Example 13, Step 1) (18.0 g, 45.3 mmol, 1 equiv.) in DCM (360 mL) was cooled (ice bath) under a nitrogen atmosphere. Dess-Martin periodinane (9.0 g, 68.0 mmol, 1.5 equiv.) was added in small portions at 0°C. The resulting reaction mixture was stirred at room temperature for 3 hours. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to 0°C, treated with 10% aqueous sodium thiosulfate solution, and then extracted with DCM (3 x 180 mL). The organic layer was washed with water, followed by brine, and concentrated under reduced pressure to give 3-(4-(4-((3,5-difluoropyridin-2-yl)methoxy)-6-methyl-2-oxopyridin-1(2H)-yl)-5-methylpyridin-2-yl)propioaldehyde (CPD-22) as a yellow liquid (16 g, 83%). The crude compound was used in the next step without further purification.

[0220] Step 3: Synthesis of 4-((3,5-difluoropyridin-2-yl)methoxy)-1-(2-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5-methylpyridin-4-yl)-6-methylpyridin-2(1H)-one (CPD-23) [ka]

[0221] To a stirred solution of 3-(4-(4-((3,5-difluoropyridin-2-yl)methoxy)-6-methyl-2-oxopyridin-1(2H)-yl)-5-methylpyridin-2-yl)propioaldehyde (CPD-22, Example 13, Step 2) (3.0 g, 7.59 mmol, 1 equiv.) in ACN (30 mL) was added NaCO (2.3 g, 22.78 mmol, 3 equiv.) and 2-hydroxy-2-methylpropionamidine HCl (INT-02, 1.17 g, 11.39 mmol, 1.5 equiv.) at room temperature. The reaction mixture was heated at 80-85 °C for 2 h. The reaction progress was monitored by TLC and LC-MS. Upon completion, the reaction mixture was cooled to room temperature. It was filtered and washed with ACN. The filtrate was concentrated under reduced pressure to give 4-((3,5-difluoropyridin-2-yl)methoxy)-1-(2-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5-methylpyridin-4-yl)-6-methylpyridin-2(1H)-one (CPD-23) as a brown solid (3.6 g, 97%) with an HPLC purity of 66%. The crude compound was used in the next step without further purification. 1H-NMR (300 MHz, CDCl3) δ ppm: 8.86 (d, J = 5.1 Hz, 1H), 8.74 (s, 1H), 8.42-8.41 (m, 1H), 8.27-8.25 (m, 2H), 7.30-7.33 (m, 1H), 6.08 (d, MS (ES) m / z = 480.89 (M+H).

[0222] Step 4: Synthesis of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-20) [ka]

[0223] A mixture of 4-((3,5-difluoropyridin-2-yl)methoxy)-1-(2-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5-methyl-pyridin-4-yl)-6-methylpyridin-2(1H)-one (CPD-23, Example 13, Step 3) (3.6 g, 7.515 mmol), N-chlorosuccinimide (1.19 g, 9.018 mmol, 1.2 equiv) in DCM (108 mL) containing dichloroacetic acid (0.387 g, 3.006 mmol, 0.4 equiv) was heated at 60° C. under nitrogen for 2 h. The reaction mixture was cooled to room temperature and diluted with DCM. It was then made basic with aqueous NaHCO3. The layers were separated. The aqueous layer was extracted with DCM. The combined extracts were washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude compound was purified by silica gel (230-400 mesh) column chromatography using 2-4% MeOH as eluent to give 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxy-propan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-20) as a yellow solid (1.2 g, 31% yield) with 92% HPLC purity. 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 8.97 (d, J = 5.2 Hz, 1H), 8.86 (s, 1H), 8.69 (s, 1H), 8.61 (d, J = 2.0 Hz, 1H), 8.24 (d, J = 5.4 Hz, 1H), 8.13-8.07 (m, 1H), 6.84 (s, 14H), 5.49 (d, J = 1.2 Hz, 2H), 5.25 (br-s, 1H), 2.17 (s, 3H), 1.98 (s, 3H), 1.54 (s, 3H), 1.53 (s, 3H). MS (ES) m / z 514.89 (M+H).

[0224] Example 14: Preparation of 2'-acetyl-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-17) via reductive cyanation [ka]

[0225] Step 1: Synthesis of 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carbonitrile (CPD-24) [ka]

[0226] To a solution of 2'-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-03, Example 5) (1 g, 2.65 mmol), zinc cyanide (186.2 mg, 1.59 mmol, 0.6 equiv), Pd2(dba)3 (48.54 mmol, 0.05 mmol, 0.02 equiv), zinc dust (6.94 mg, 0.11 mmol, 0.04 equiv), and diphenylphosphinoferrocene (176.4 mg, 0.32 mmol, 0.12 equiv) were added sequentially, and the reaction mass was degassed with nitrogen for 30 minutes. The reaction mixture was heated to 120 °C for 18 hours. The reaction was monitored by LCMS, which showed approximately 59% of the desired mass and approximately 5% of 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using a 1:1 mixture of ethyl acetate and hexane to give the desired product 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carbonitrile (CPD-24) (400 mg, 41%) with a purity of 75%. 1H-NMR (300 MHz, DMSO-d6) δ ppm: 8.84 (brs, 1H), 8.59 (d, 1H, J= 2.1 Hz), 8.12 (s, 1H), 8.11-8.04 (m, 1H), 6.12 (d, 1H, J=1.5 Hz), 6.05 (d, 1H, 2.4 Hz), 5.25 (2, 2H), 2.10 (s, 3H), 1.84 (s, 1H). MS (ES) m / z 369.20 (M+H).

[0227] Step 2: Synthesis of 2'-acetyl-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-17) [ka]

[0228] To a solution of 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carbonitrile (CPD-24, Example 14, Step 1) (50 mg, 0.136 mmol) in THF (5 mL) was added 3 M methylmagnesium iodide in THF (0.0.2 mL, 0.6 mmol, 4.4 equiv.) at room temperature. The reaction mixture was stirred at room temperature for 12 hours. It was quenched with saturated ammonium chloride solution (0.5 mL). The organic layer was separated and concentrated. Crude 2'-acetyl-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-17) was isolated and analyzed by MS(ES) m / z 386.29 (M+H).

[0229] Example 15: Preparation of methyl 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (CPD-04) via a brominated intermediate [ka]

[0230] Step 1: Synthesis of 2'-bromo-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-25) [ka]

[0231] A stirred mixture of 2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-02, Example 3) (10.0 g, 40 mmol, 1 equiv.), 33% HBr in AcOH (150 mL, 15 vol.), and NaBr (4.115 g, 40 mmol, 1 equiv.) was heated to 90°C for 36 h. Upon completion, the reaction mixture was cooled to room temperature. The solid was filtered and dried to give 2'-bromo-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-25) as a light gray solid (14 g, crude) with a crude HPLC purity of 88%. 1 H-NMR (400 MHz), DMSO-d6δ: 10.78 (brs, 1H), 8.48 (s, 1H), 7.69 (s, 1H), 6.03-6.02 (m, 1H), 5.65 (d, J = 2.4 Hz, 1H), 1.96 (s, 3H), 1.84 (s,3H). MS (ES) m / z 296 (M+H).

[0232] Step 2: Synthesis of 2'-bromo-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-26) [ka]

[0233] To a stirred suspension of 2'-bromo-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-25, Example 15, Step 1) (14 g, 37.4 mmol, 1 equiv.) in DMF (56 mL, 4 vol.) was added K2CO3 (12.9 g, 93.5 mmol, 2.5 equiv.), followed by a solution of 2-(chloromethyl)-3,5-difluoro-pyridine (INT-01, Example 4) (6.73 g, 41.1 mmol, 1.1 equiv.) in DMF (14 mL, 1 vol.). The resulting reaction mixture was stirred at room temperature for 32 h (the reaction mixture turned pale green after 10 min). The reaction progress was monitored by TLC. Upon completion, the reaction mixture was quenched with ice-cold water (140 mL) and extracted with EtOAc (2 x 140 mL). The combined organic layers were washed with water (70 mL) followed by brine (70 mL) and concentrated under reduced pressure to give 2'-bromo-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-26) as a dark liquid (12.5 g, 79%) with an HPLC purity of 81%. 1 H - NMR (400 MHz, DMSO-d6) δ ppm: 8.59 (d, J = 2.4 Hz, 1H), 8.47 (s, 1H), 8.09-8.04 (m, 1H), 7.72 (s, 1H), 6.13-6.12 (d, 1H, J=2.4 Hz), 6.03 (d, J = 2.4 Hz, 1H), 5.24 (d, J = 1.6 Hz, 2H), 1.96 (s, 3H), 1.85 (s, 3H). MS (ES) m / z 423.91 (M+2H).

[0234] Step 3: Synthesis of methyl 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (CPD-04) [ka]

[0235] A pre-cleaned 600 mL autoclave was charged under argon with 2'-bromo-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-26, Example 15, Step 2) (4 g, 9.5 mmol), followed by methanol (64 mL, 16 vol) and DMF (64 mL, 16 vol). The reaction mixture was degassed with argon for 15 min. Triethylamine (2.61 mL, 19.0 mmol, 2 equiv.) was added, and the mixture was degassed with argon for another 15 min. Pd(dppf)Cl·DCM complex (0.775 g, 0.95 mmol, 0.1 equiv.) was added, and the autoclave was closed. Carbon monoxide gas was introduced at 100 psi, and the pressure was released. It was repressurized to 200 psi with CO gas, and the reaction mass was stirred and heated at 100°C for 16 h. The reaction was monitored by TLC and LCMS. The reaction mixture was distilled to remove volatiles. It was filtered through a pad of Celite, and the pad was washed with EtOAc (2 x 40 mL). The filtrate was stirred with ice-cold water (640 mL) and extracted with EA (3 x 500 mL). The combined extracts were washed with water and dried over Na2SO4. 、 Concentration under reduced pressure gave crude CPD-04, which was suspended in MTBE, stirred for 1 hour, and filtered to give methyl 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (CPD-04) as a brown solid (3.1 g, 81%) with an HPLC purity of 77%. 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 8.79 (s, 1H), 8.59 (d, J = 2.0 Hz, 1H), 8.10-8.05 (m, 1H), 7.92 (s, 1H), 6.14-6.13 (m, 1H), 6.04 (d, J = MS (ES) m / z 402.09 (M+H).

[0236] Example 16: Preparation of 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-11) from methyl 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (CPD-04) [ka]

[0237] To a stirred suspension of methyl 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (CPD-04, Example 6) in THF (5 volumes), a solution of LiOH·HO (3.0 equiv.) in water (5 volumes) was added at 25-35°C, and stirring of the reaction mass was continued for 2-4 hours. The progress of the reaction was monitored by TLC. The aqueous layer was then washed with EtOAc (5 volumes), and the pH of the aqueous layer was adjusted to 2-3 using 4 M HCl solution. The aqueous layer was extracted with DCM (3 times 10 volumes). The combined DCM layers were dried over sodium sulfate and concentrated under reduced pressure below 40°C to give 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid as a light brown solid with an HPLC purity of 98.7% and an atropisomer ratio of 51.5%:48.5%. 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 13.26 (br s, 1H) 8.77 (s, 1H), 8.59 (s, 1H), 8.07-8.15 (m, 1H), 7.88 (s, 1H), 6.13 (s, 1H), 6.04 (d, J = 2.4 Hz, 1H), 5.25 (d, J = 1.6 Hz, 2H), 2.08 (s, 3H), 1.82 (s, 3H). MS (ES) m / z 388.17 (M+H).

[0238] Example 17: Preparation of (P)-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-12) [ka]

[0239] The racemic mixture of atropisomers 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (Example 16) was separated using supercritical fluid chromatography (SFC) (see Table 3). After concentration, the chiral purity of fraction-1 ((P)-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid) was isomer 1:isomer 2 (97.7%:2.3%), respectively. 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 13.26 (br s, 1H) 8.75 (s, 1H), 8.59 (d, J =2.8 Hz, 1H), 8.12-8.05 (m, 1H), 7.91 (s, 1H), 6.13 (d, J = 2.0 MS (ES) m / z 388.17 (M+H), the HPLC chiral purity of the separated fraction-2 ((M)-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid) is isomer 1:isomer 2 (2.7%:97.3%). 1H-NMR (400 MHz, DMSO-d6) δ ppm: 13.24 (br s, 1H) 8.76 (s, 1H), 8.59 (d, J =2.0 Hz, 1H), 8.13-8.05 (m, 1H), 7.91 (s, 1H), 6.13 (d, J = 1.6 MS (ES) m / z 388.17 (M+H).

[0240] [Table 3]

[0241] Example 18: Alternative preparation of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-07) via chiral separation using (S)-1-(naphthalen-2-yl)ethan-1-amine [ka]

[0242] Step 1: Synthesis of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (A salt of isomer 1) [ka]

[0243] To the filtered mother liquor (F mL) from Example 9, Step 3 (1 g, Isomer 1:Isomer 2, 8:91) was added toluene (10 volumes) at 25-35°C. The reaction mass temperature was then increased to 110-115°C and stirred at 110-115°C for 48 hours. An aliquot of solid was removed from the heterogeneous mixture and filtered. The solid was analyzed by chiral HPLC to confirm the salt configuration as the desired isomer. The reaction mass was filtered and dried under vacuum to give the chiral amine salt, (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium of Isomer 1 (A salt of Isomer 1) with chiral purity of Isomer 1:Isomer 2 (96.1%:3.1%) and HPLC purity of 98.4%.

[0244] Step 2: Synthesis of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxylic acid (CPD-07). The resulting chiral amine salt from Example 18, Step 1 ((P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (A salt of Isomer 1) (0.6 g, Isomer 1:Isomer 2 (96.1%:3.1%)) was dissolved in water (6.0 mL), made basic (pH ∼12) using 2N NaOH, and extracted with MTBE. The resulting MTBE layer containing the amine was discarded. The pH of the aqueous layer was adjusted to pH=2 with HCl. Precipitation of a solid was observed. The precipitated solid was washed and dried under vacuum to give 0.4 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid with an HPLC chiral purity of isomer 1:isomer 2 (95.22%:4.78%) and an HPLC purity of 98.16%. 1H-NMR (400 MHz, DMSO-d6): δ ppm 13.35 (br s, 1H), 8.80 (s, 1H), 8.60 (d, 1H, J = 2.4 Hz), 8.07-8.12 (m, 1H), 7.97 (s, 1H), 6.80 (s, 1H), 5.47 (d, 2H, J = 1.6 Hz), 2.08 (s, 3H), 1.93 (s, 3H). MS (ES) m / z 422.12 (M+H).

[0245] Example 19: Preparation of 2'-acetyl-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-17) from CPD-03 [ka]

[0246] Step 1: Synthesis of 2'-(1-butoxyvinyl)-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-27). To a stirred suspension of 2'-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-03, Example 5) (3.0 g, 7.94 mmol) in iPrNEt (2.8 mL, 16.08 mmol) was added ethylene glycol (15 mL) and butyl vinyl ether (5.1 mL). The mixture was stirred and warmed to 35 °C in an oil bath while N was bubbled through the mixture. Solid Pd(OAc) (0.10 g, 0.397 mmol, 5 mol%) and 1,1′-ferrocenediyl-bis(diphenylphosphine) (dppf) (0.44 g, 0.795 mmol, 10 mol%) were sequentially charged to the mixture, and the oil bath was heated to 110 °C. After 3 h at 110 °C and another 3 h at 120 °C, the reaction was ≥95% complete by IPC-LCMS. The mixture was cooled and partitioned between water and EtOAc. The aqueous phase was extracted again with EtOAc. The combined organic phases were washed with water and filtered through a pad of silica gel, eluting with EtOAc until all the enol ether product was recovered. The product-containing fractions were evaporated to give 0.310 g of 2'-(1-butoxyvinyl)-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-27) as a tan solid with 80% HPLC purity (yield: 10%). 1 H-NMR (400 MHz, CDCl3) δ ppm: 8.56 (s, 1H), 8.40 (s, 1H), 7.41 (s, 1H), 7.24-7.32 (m, 2H), 6.04 (s, 1H), 5.96 (s, 1H), 5.44 (s, 1H), 5.19 (s, 2H), 4.36 3.84-3.91 (m, 2H), 2.11 (s, 3H), 1.85 (s, 3H), 1.72-1.80 (m, 2H), 1.42-1.51 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H); MS (ES) m / z 386.29 (M+H).

[0247] Step 2: Synthesis of 2'-acetyl-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-17). 2'-(1-Butoxyvinyl)-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-27, Example 19, Step 1) (0.250 g, 0.663 mmol) was treated with 8 mL of 3N HCl at room temperature. After 30 minutes of vigorous stirring, the reaction was complete by IPC-HPLC. The mixture was transferred to a separatory funnel containing EtOAc and water. A small amount of saturated aqueous NaCl was added, and the mixture was mixed well and allowed to separate. The layers were separated, and the aqueous phase was neutralized (KPO / KOH aqueous solution) and extracted again with EtOAc. The combined organic extracts were washed with water, and both aqueous phases were back-extracted again with EtOAc. All organic phases were combined and vacuum filtered through a pad of silica gel. The filtrate was evaporated, and the residue was chromatographed on silica gel using 0–30% 2-methyltetrahydrofuran / EtOAc. All fractions containing the desired product were pooled and evaporated. The residue was further dried on a high vacuum line to give 0.152 g (70% yield) of 2′-acetyl-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2H-[1,4′-bipyridin]-2-one (CPD-17) as a tan foam. 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 8.68 (s, 1H), 8.41 (s, 1H), 7.81 (s, 1H), 7.30-7.36 (m, 1H), 6.06 (s, 1H), 5.96 (s, 1H), 5.18 (s, 2H), 2.73 (s, 3H), 2.20 (s, 3H), 1.83 (s, 3H); MS (ES) m / z 385.15 (M+H).

[0248] Example 20: Alternative preparation of 2'-acetyl-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-17) from CPD-26 [ka]

[0249] Step 1: Synthesis of 2'-(1-butoxyvinyl)-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-27). To a stirred suspension of 2'-bromo-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-26) (Example 15, Step 2, 5.0 g, 11.84 mmol) was added iPrNEt (4.1 mL, 23.68 mmol), butyl vinyl ether (7.7 mL, 59.21 mmol), and ethylene glycol (25 mL) under N. The mixture was warmed to 40 °C in an oil bath with stirring while N was bubbled through the mixture. Solid Pd(OAc) (0.11 g, 0.474 mmol, 4 mol%) and dppf (0.53 g, 0.947 mmol, 8 mol%) were added sequentially, and the oil bath was heated to 100 °C. After a total of 15 h at 100 °C, the desired product was ≥98% by IPC-HPLC. The mixture was cooled to room temperature and treated with 8 mL of 3 N HCl. After 30 min of vigorous stirring, the reaction was complete (HPLC). The mixture was transferred to a separatory funnel containing EtOAc and water. A small amount of saturated aqueous NaCl was added, and the mixture was mixed well and allowed to separate. The layers were separated, and the aqueous phase was neutralized (aqueous KPO / KOH) and re-extracted with EtOAc. The combined organic extracts were washed with water, and both aqueous phases were back-extracted again with EtOAc. The combined organic layers were vacuum-filtered through a pad of silica gel. The filtrate was evaporated, and the residue was chromatographed on silica gel with 0–30% 2-methyltetrahydrofuran / EtOAc. The combined desired fractions were concentrated and dried under high vacuum to give 2.35 g of 2'-(1-butoxyvinyl)-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-27) as a tan foam (yield: 52%). 1H NMR (400 MHz, CDCl3) δ ppm: 8.56 (s, 1H), 8.40 (s, 1H), 7.41 (s, 1H), 7.24-7.32 (m, 2H), 6.04 (s, 1H), 5.96 (s, 1H), 5.44 (s, 1H), 5.19 (s, 2H), 4.36 3.84-3.91 (m, 2H), 2.11 (s, 3H), 1.85 (s, 3H), 1.72-1.80 (m, 2H), 1.42-1.51 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H); MS (ES) m / z 386.29 (M+H).

[0250] Step 2: Synthesis of 2'-acetyl-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-17). To a stirred suspension of 2'-(1-butoxyvinyl)-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-27) (Example 20, Step 1, 2.0 g, 5 mmol), 2-methyltetrahydrofuran was added, followed by 3N HCl to bring the pH to approximately 2. The resulting mixture was stirred vigorously at room temperature for 30 minutes, at which point the reaction was complete. The acid was neutralized with saturated KHCO (CO off-gassing), and the product was extracted into two small portions of EtOAc. The combined organic phase was washed twice with water and then filtered through a silica gel pad, eluting with EtOAc. The combined desired fractions were concentrated and then further dried on a high vacuum line to give 1.46 g of 2'-acetyl-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-17) as a free-flowing pale yellow foam (yield: 70%). 1H NMR (400 MHz, CDCl3) δ ppm: 8.68 (s, 1H), 8.40 (s, 1H), 7.81 (s, 1H), 7.30-7.36 (m, 1H), 6.03 (s, 1H), 5.97 (s, 1H), 5.19 (s, 2H), 2.72 (s, 3H), 2.20 (s, 3H), 1.83 (s, 3H): MS (ES) m / z 386.29 (M+H).

[0251] Example 21: Alternative preparation of 2'-acetyl-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CDP-17) from CPD-26 [ka]

[0252] To a stirred suspension of 2'-bromo-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-26) (Example 15, Step 2, 5.0 g, 11.84 mmol) under N was added iPrNEt (4.1 mL, 23.68 mmol), hydroxyethyl vinyl ether (5.3 mL, 59.2 mmol), NMP (13 mL), and water (13 mL). The mixture was stirred and warmed to 45 °C while N was bubbled through the mixture. Solid Pd(OAc) (0.08 g, 0.36 mmol, 3 mol%) and 1,3-bis(diphenylphosphino)propane (dppp) (0.29 g, 0.71 mmol, 6 mol%) were added sequentially, and the oil bath was heated to 95 °C for 24 h until the desired product was 91.8% by IPC-HPLC. The mixture was cooled to give a clear, light brown solution. The mixture was diluted with 2-methyltetrahydrofuran, treated with 3 N HCl to a pH of approximately 2, and stirred vigorously at room temperature for 30 min. IPC-HPLC indicated that no starting material remained. The acid was neutralized with saturated KHCO (CO off-gassing), and the product was extracted into two small portions of EtOAc. The combined organic phase was washed twice with water and then filtered through a pad of silica gel, eluting with EtOAc. The combined desired fractions were concentrated and dried under high vacuum to give 3.8 g of 2'-acetyl-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CDP-17) as a free-flowing pale yellow foam (yield: 70%). 1 H NMR (400 MHz, CDCl3) δ ppm: 8.68 (s, 1H), 8.40 (s, 1H), 7.81 (s, 1H), 7.30-7.36 (m, 1H), 6.03 (s, 1H), 5.97 (s, 1H), 5.19 (s, 2H), 2.72 (s, 3H), 2.20 (s, 3H), 1.83 (s, 3H): MS (ES) m / z 386.26 (M+H).

[0253] Example 22: Alternative preparation of 2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-18) from CPD-28 [ka]

[0254] To a stirred suspension of 2',3-dichloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-28) (Example 40, 1 g, 2.43 mmol, 1 equiv.) in 1,4-dioxane (7.5 ml, 7.5 volumes), tributyl-(1-ethoxyvinyl)stannane (1.228 g, 3.640 mmol, 1.5 equiv.) was added under an argon atmosphere at room temperature. The reaction mass was degassed with argon for 10 minutes. Copper iodide (23.13 mg, 0.121 mmol, 0.05 equiv.) and Pd(dppf)Cl₂·DCM complex (79.47 mg, 0.0973 mmol, 0.04 equiv.) were added under an argon atmosphere. The reaction mass was degassed with argon for 5 minutes. The reaction mixture was heated in an oil bath at 100-105°C for 16 hours and was 86% complete by IPC-LCMS. The reaction mixture was cooled to room temperature, diluted with 1,4-dioxane (5 ml), filtered through Celite, and washed with 1,4-dioxane. The combined organic layers were concentrated to 50% and cooled to 0-5°C. 36% HCl (1 ml, 1 volume) was added slowly below 5°C and the reaction mass was stirred for 1 hour. The reaction mass slowly solidified, diluted with petroleum ether, and filtered. The solid was suspended in DCM (20 ml), cooled to 0-5°C, and basified with 20% NaOH (aq) solution. The two layers were separated, and the aqueous layer was extracted again with DCM (10 ml). The combined organic layers were dried over Na2SO4 and evaporated to give the crude compound. The crude compound was purified by column chromatography using 100-200 mesh silica gel. The combined desired fractions were concentrated and dried under high vacuum to give 800 mg of 2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-18) as an off-white solid (yield: 78%). 1H-NMR (400 MHz, DMSO-d6) δ ppm: 8.70 (s, 1H), 8.40 (d, 1H, J= 2.4 Hz), 7.78 (s, 1H), 7.34 (m, 1H), 6.37 (s, 1H), 5.41 (d, 2H, J= 1.6 MS (ES) m / z 420.14 (M+H).

[0255] Example 23: Alternative preparation of 2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-18) from CPD-28 [ka]

[0256] Step 1: Synthesis of 2'-(1-butoxyvinyl)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-29). To a stirred suspension of 2',3-dichloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-28) (Example 40, 5.0 g, 12.13 mmol), iPrNEt (4.2 mL, 24.26 mmol), butyl vinyl ether (1.9 mL, 14.56 mmol, 1.2 equiv.), and ethylene glycol (25 mL) were added. While bubbling N through the mixture, the mixture was warmed to 35 °C in an oil bath with stirring. Solid Pd(OAc) (0.14 g, 0.606 mmol, 5 mol%) and dppf (0.67 g, 1.21 mmol, 10 mol%) were sequentially charged to the mixture, and the oil bath was heated to 115 °C for 9 h. The mixture was cooled to room temperature and partitioned between water and EtOAc. The aqueous phase was re-extracted with EtOAc, and the combined organic phases were washed twice with water and filtered through a silica gel pad, eluting with EtOAc. The combined desired fractions were concentrated and dried under high vacuum to give 2'-(1-butoxyvinyl)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-29) as a tan foam. The material was carried on to Step 2 without further purification. 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 8.55 (s, 1H), 8.38 (s, 1H), 7.37 (s, 1H), 7.28-7.36 (m, 1H), 6.35 (s, 1H), 5.44 (s, 1H), 5.38 (s, 2H), 4.36 (s, 1H), 3.84-3.91 (m, 2H), 2.07 (s, 3H), 1.93 (s, 3H), 1.70-1.78 (m, 2H), 1.40-1.49 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H); MS (ES) m / z 476.10 (M+H).

[0257] Step 2: Synthesis of 2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-18). The mixture from Step 1 containing 2'-(1-butoxyvinyl)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-29) (Step 1) was treated with 8 mL of 3N HCl at room temperature. After 30 minutes of vigorous stirring, IPC-HPLC indicated no starting material remained. The mixture was partitioned between EtOAc and brine. The aqueous phase was neutralized (aqueous KPO / KOH) and extracted again with EtOAc. The combined organic extracts were washed with water, and both aqueous phases were back-extracted again with EtOAc. All organic phases were combined and vacuum filtered through a silica gel pad. The filtrate was evaporated, and the residue was chromatographed on silica gel using 0-30% 2-methyltetrahydrofuran / EtOAc. The combined desired fractions were concentrated and dried under high vacuum to give 2.35 g of 2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-18) as a light tan foam (yield: 52%). 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 8.70 (s, 1H), 8.40 (d, 1H, J= 2.4 Hz), 7.78 (s, 1H), 7.34 (m, 1H), 6.37 (s, 1H), 5.41 (d, 2H, J= 1.6 MS (ES) m / z 420.14 (M+H).

[0258] Example 24: Alternative preparation of 2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-18) from CPD-30 [ka]

[0259] Step 1: Synthesis of 2'-(1-butoxyvinyl)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-29). To a stirred suspension of 2'-bromo-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-30) (Example 37, 7.0 g, 15.33 mmol), iPrNEt (5.3 mL, 30.66 mmol), hydroxyethyl vinyl ether (56.9 mL, 76.64 mmol), NMP (18 mL), and water (18 mL) were added. The mixture was stirred and warmed to 45 °C while N was bubbled through the mixture. Solid Pd(OAc)2 (0.1 g, 0.46 mmol, 3 mol%) and 1,3-bis(diphenylphosphino)propane (dppp) (0.38 g, 0.92 mmol, 6 mol%) were added sequentially, and the oil bath was heated to 92 °C. Heating at 92–94 °C was continued for 28 h, and the reaction progress was monitored by HPLC and TLC. The conversion was initially very slow, so small amounts of additional Pd(OAc)2 were charged after approximately 3 and 21 h of heating. The reaction was complete after 28 h of heating but never became homogeneous. The mixture was cooled to room temperature and partitioned between water and EtOAc. The aqueous phase was extracted again with EtOAc, and the combined organic phases were washed twice with water and filtered through a pad of silica gel, eluting with EtOAc. The combined desired fractions were concentrated and dried under high vacuum to give 1.03 g of 2'-(1-butoxyvinyl)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-29) as a tan foam (yield: 15%). The material was carried on to Step 2 without further purification. 1H-NMR (400 MHz, DMSO-d6) δ ppm: 8.55 (s, 1H), 8.38 (s, 1H), 7.37 (s, 1H), 7.28-7.36 (m, 1H), 6.24 (s, 1H), 5.44 (s, 1H), 5.38 (s, 2H), 4.32 (s, 1H), 3.83-3.90 (m, 2H), 2.07 (s, 3H), 1.92 (s, 3H), 1.70-1.77 (m, 2H), 1.40-1.49 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H); MS (ES) m / z 476.08 (M+H).

[0260] Step 2: Synthesis of 2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-18). The stirred mixture of 2'-(1-butoxyvinyl)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-29) (Step 1) was treated with 8 mL of 3N HCl at room temperature. After 30 minutes of vigorous stirring, IPC-HPLC indicated that no starting material remained. The mixture was partitioned between EtOAc and brine. The aqueous phase was neutralized (aqueous KPO / KOH) and extracted again with EtOAc. The combined organic extracts were washed with water, and both aqueous phases were back-extracted again with EtOAc. All organic phases were combined and vacuum filtered through a silica gel pad. The filtrate was evaporated, and the residue was chromatographed on silica gel using 0-30% 2-methyltetrahydrofuran / EtOAc. The combined desired fractions were concentrated and dried under high vacuum to give 1.2 g of 2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-18) as an off-white solid (yield: 75%). 1H-NMR (400 MHz, DMSO-d6) δ ppm: 8.70 (s, 1H), 8.40 (d, 1H, J= 2.4 Hz), 7.78 (s, 1H), 7.34 (m, 1H), 6.37 (s, 1H), 5.41 (d, 2H, J= 1.6 MS (ES) m / z 420.14 (M+H).

[0261] Example 25: Alternative preparation of 2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-18) from CPD-30 [ka]

[0262] To a stirred suspension of 2'-bromo-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-30) (Example 37, 7.0 g, 15.33 mmol) under N was added iPrNEt (5.3 mL, 30.66 mmol), hydroxyethyl vinyl ether (56.9 mL, 76.64 mmol), NMP (18 mL), and water (18 mL) in a round-bottom flask equipped with a stir bar and a condenser. The mixture was stirred and warmed to 45 °C while N was bubbled through the mixture. Solid Pd(OAc) (0.1 g, 0.46 mmol, 3 mol%) and dppp (0.38 g, 0.92 mmol, 6 mol%) were added sequentially, and the oil bath was heated to 92 °C. Heating at 92-94 °C was continued for 28 h, and reaction progress was monitored by HPLC and TLC. Conversion was initially very slow, so small amounts of additional Pd(OAc) were charged after approximately 3 and 21 h of heating. The reaction was complete after 28 h of heating but had not become homogeneous. The mixture was cooled, diluted with 2-methyltetrahydrofuran, treated with 3 N HCl to a pH of approximately 2, and stirred vigorously at room temperature for 30 min. The acid was neutralized with saturated KHCO (CO off-gassing), and the product was extracted into two small portions of EtOAc. The combined organic phase was washed twice with water and then filtered through a pad of silica gel, eluting with EtOAc. The combined desired fractions were concentrated and dried under high vacuum to give 1.4 g of 2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-18) as an off-white solid (yield: 20%). 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 8.70 (s, 1H), 8.40 (d, 1H, J= 2.4 Hz), 7.78 (s, 1H), 7.34 (m, 1H), 6.38 (s, 1H), 5.42 (d, 2H, J= 1.6 MS (ES) m / z 420.12 (M+H)..

[0263] Example 26: Alternative preparation of methyl 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (CDP-05) from CPD-28 [ka]

[0264] To a stirred suspension of 2',3-dichloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-28) (Example 41, 50.0 g, 1.0 equiv.) in methanol (400 mL, 8.0 vol.) was added TEA (36.8 g, 3.0 equiv.) at 25-30 °C and purged with argon gas for 30 minutes. Pd(dppf)Cl2 (2.4 g, 0.05 equiv.) was then added and purged with argon gas for 30 minutes. CO pressure of 60-70 psi (5 Kg) was applied and the pressure was released. CO pressure was repressurized with 75-100 psi (7 Kg) and the reaction mass was slowly heated to 90-95 °C and maintained at the same temperature for 16 hours. The progress of the reaction was monitored by TLC / IPC-HPLC. After completion of the reaction, the reaction mass was cooled to room temperature, diluted with DCM (100 mL, 2 volumes), and stirred for 15-30 minutes. The reaction mass thus obtained was filtered through a hyflo bed. The filtrate was distilled under reduced pressure below 55°C to obtain a crude residue. IPA (250 mL, 5.0 volumes) was added at 25-35°C and stirred for 10-12 hours. The solid was filtered and washed with IPA (50 mL, 1 volume). After drying under vacuum below 50°C, 34.39 g of methyl 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (CPD-05) was obtained as a light brown solid with an HPLC purity of 95.3% (yield: 66.8%). 1H-NMR (400 MHz, DMSO-d6) δ ppm: 8.82 (s, 1H), 8.6 (d, J = 2.4 Hz, 1H), 8.13-8.07 (m, 1H), 8.03 (s, 1H), 6.81 (s, 1H), 5.48 (d, J = 1.6 Hz, 2H), 3.89 (s, 3H), 1.92 (s, 3H), 1.81 (s, 3H); MS (ES) m / z 436.10 (M+H).

[0265] Example 27: Alternative preparation of methyl 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (CDP-05) from CPD-30 [ka]

[0266] To a stirred solution of 2'-bromo-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-30) (Example 38, 3 g, 6.593 mmol, 1 equiv.) in dry methanol (45 ml, 15 volumes) in a clean steel bomb, dppf (182 mg, 0.329 mmol, 0.05 equiv.) and TEA (2 g, 19.78 mmol, 3 equiv.) were added at room temperature under an argon atmosphere. The reaction mass was degassed with argon for 10 minutes, followed by the addition of Pd(OAc)2 (73.9 mg, 0.329 mmol, 0.05 equiv.) under an argon atmosphere. The reaction mass was degassed with argon for 5 minutes. The steel bomb was closed, pressurized with CO gas (100 psi), and opened. The mixture was repressurized with CO gas (100 psi) and the magnetically stirred reaction mixture was heated in an oil bath at 80-85°C for 18 hours. The reaction was monitored by IPC-LCMS, which showed approximately 93.1% of the desired mass. The reaction mixture was cooled to room temperature, filtered through a celite bed, and the filtrate was concentrated to give 2.2 g of crude product. The celite bed was placed in a round-bottom flask, suspended in 20% MeOH / DCM (100 ml), stirred for 30 minutes, and filtered. The filtrate was concentrated under reduced pressure to give a solid (200 mg). The combined solids were taken up in ethyl acetate (25 ml) and stirred for 30 minutes, then filtered and dried to give 2.2 g of methyl 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (CPD-05) as a light brown solid (yield: 78%). 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 8.59 (d, J = 2.4 Hz, 1H), 8.82 (s, 1H), 8.12-8.02 (m, 2H), 7.80 (s, 1H), 6.72 (s, 1H), 5.47 (s, 2H), 3.89 (s, 3H), 2.08 (s, 3H), 1.92 (s, 3H); MS (ES) m / z 435.90 (M+H).

[0267] Example 28: Alternative Preparation of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CDP-16) from CPD-28 [ka]

[0268] To a stirred suspension of 2',3-dichloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-28) (Example 41, 500 mg, 1.2165 mmol, 1 equiv.) in toluene (12.5 mL, 25 vol.) in a steel bomb was added N,O-dimethylhydroxylamine hydrochloride (237.2 mg, 2.433 mmol, 2 equiv.), Xantphos (28.1 mg, 0.048 mmol, 0.04 equiv.), and KPO (796.6 mg, 3.649 mmol, 3 equiv.) under an argon atmosphere at room temperature. The reaction mass was degassed with argon for 10 minutes, and then Pd(OAc) (10.92 mg, 0.0486 mmol, 0.04 equiv.) was added under an argon atmosphere. The reaction mass was degassed again with argon for 5 minutes. The steel bomb was closed and filled with CO gas (200 psi), and the reaction mixture was magnetically stirred and heated to 120 °C in an oil bath for 3.5 days. IPC-LCMS showed 68.38% of the desired material. The reaction mixture was cooled to room temperature, diluted with EtOAc, and filtered through a bed of Celite. The filtrate was concentrated and dried under high vacuum to give 248 mg of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CPD-16) as a light brown solid (yield: 45%). MS(ES) m / z 465.21(M+H).

[0269] Example 29: Alternative Preparation of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CDP-16) from CPD-30 [ka]

[0270] To a stirred suspension of 2'-bromo-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-30) (Example 38, 500 mg, 1.098 mmol, 1 equiv.) in toluene (25 mL, 50 vol.) in a steel bomb, N,O-dimethylhydroxylamine hydrochloride (214.2 mg, 2.197 mmol, 2 equiv.), Xantphos (25.37 mg, 0.0439 mmol, 0.04 equiv.), and KPO (719.6 mg, 3.54 mmol, 3 equiv.) were added at room temperature under an argon atmosphere. The reaction mass was degassed with argon for 10 minutes, and then Pd(OAc)2 (9.86 mg, 0.0439 mmol, 0.04 equiv.) was added under an argon atmosphere. The reaction mass was degassed again with argon for 5 minutes. The steel bomb was closed, filled with CO gas (200 psi), degassed, and the reaction mixture was magnetically stirred and heated in an oil bath at 100-110 °C for 18 hours. The reaction was monitored by IPC-LCMS, which showed 71.51% of the desired material. The reaction mixture was cooled to room temperature, diluted with EtOAc, and filtered through a bed of Celite. The combined organic layers were concentrated under reduced pressure. The crude product was purified by prep-HPLC. The combined desired fractions were concentrated under reduced pressure to remove volatiles, basified with aqueous NaHCO, extracted with DCM, dried over NaSO, and concentrated under reduced pressure to give 280 mg of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5′,6-trimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxamide (CPD-16) as an off-white solid (yield: 39.22%). 1H-NMR (400 MHz, DMSO-d6) δ ppm: 8.70 (s, 1H), 8.59 (d, J = 2.4 Hz, 1H), 8.12-8.06 (m, 1H,), 7.63 (s, 1H), 6.79 (s, 1H), 5.47 (s, 2H), 3.68 (s, 3H), 3.29 (s, 3H), 2.05 (s, 3H), 1.93 (s, 3H); MS (ES) m / z 465.16 (M+H).

[0271] Example 30: Alternative preparation of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CDP-16) from CPD-15 [ka]

[0272] To a stirred suspension of 4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CPD-15) (8.5 g, 19.76 mmol) in IPA (15.0 volumes) was added dichloroacetic acid (0.25 equiv.) at 25-30 °C. The reaction mixture was then heated to 45-50 °C, and N-chlorosuccinimide (1.0 equiv.) was added portionwise to the reaction mass at 45-50 °C, and the reaction mass was further heated to 60-65 °C. After completion of the reaction (by TLC), the reaction mass was cooled to room temperature and further cooled to 0-5°C, and the resulting solid was filtered, washed with IPA (1 vol) and dried to give 4.5 g of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CPD-16) as a tan solid with HPLC purity of 96.43% (yield: 49%). 1H-NMR (400 MHz, DMSO-d6) δ ppm: 8.69 (s, 1H), 8.59 (d, J = 2.4 Hz, 1H), 8.12-8.07 (m, 1H,), 7.63 (s, 1H), 6.80 (s, 1H), 5.47 (s, 2H), 3.68 (s, 3H), 3.30 (s, 3H), 2.05 (s, 3H), 1.92 (s, 3H); MS (ES) m / z 465.12 (M+H).

[0273] Example 31: Preparation of 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CDP-11) from CPD-03 [ka]

[0274] To a solution of 2'-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-03, Example 5, 1 g, 2.64 mmol, 1 equiv.) in methanol and water (20 ml, 20 volumes, 9:1) in a steel bomb, with magnetic stirring, Na2CO3 (420.8 mg, 3.97 mmol, 1.5 equiv.) was added at room temperature under an argon atmosphere. The reaction mass was degassed with argon for 15 minutes. Then, Pd(dppf)Cl2·DCM complex (108.53 mg, 0.132 mmol, 0.05 equiv.) was added under an argon atmosphere. The reaction mass was degassed with argon for 5 minutes. The steel bomb was closed, filled with CO gas (50 psi), and opened. The reaction mixture was recharged with CO gas (100 psi) and heated to 90–95°C in an oil bath with magnetic stirring for 17 h. The reaction was monitored by IPC-LCMS until the desired product was >80%. The reaction mass was cooled to room temperature, diluted with methanol, and filtered through a bed of Celite. The filtrate was concentrated under reduced pressure, and the crude product was diluted with water (20 ml) and washed with ethyl acetate (2 x 20 ml). The aqueous layer was acidified with 1N aqueous citric acid and extracted with 10% MeOH / DCM. The combined organic layers were dried over NaSO and evaporated under reduced pressure to give 700 mg of 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-11) as an off-white solid with an HPLC purity of 99.36% (yield: 71%). 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 13.24 (brs, 1H), 8.76 (s, 1H), 8.59 (d, 1H, 2.4 Hz), 8.10 (m, 1H), 7.87 (s, 1H), 6.13 (d, 1H, J=2 Hz), 6.04 (d, 1H, J=2.4 Hz), 5.24 (s, 2H), 2.08 (s, 3H), 1.82 (s, 3H); LCMS (ES) m / z 387.99 (M+H).

[0275] Example 32: Preparation of 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CDP-11) from CPD-26 [ka]

[0276] To a suspension of 2'-bromo-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-26) (Example 15, Step 2, 200 mg, 0.473 mmol, 1 equiv.) in methanol and water (3.6 mL:0.4 mL, 20 volumes, 9:1), triethylamine (0.194 mL, 1.421 mmol, 3 equiv.) and dppf (13.1 mg, 0.0236 mmol, 0.05 equiv.) were added under a nitrogen atmosphere at room temperature. The reaction mass was degassed with argon for 15 minutes. Then, Pd(OAc)2 (5.3 mg, 0.0236 mmol, 0.05 equiv.) was added under an argon atmosphere. The reaction mass was degassed with argon for 5 minutes, and then the vial was placed in a clean, dry steel bomb. The steel bomb was closed, filled with CO gas (50 psi), and opened. CO gas (100 psi) was charged, and the reaction mixture was magnetically stirred and heated in an oil bath at 90-95 °C for 16 hours. The reaction was monitored by LCMS until approximately 65.2% of the desired mass was observed. The pressure was released, the vial was removed, and the mixture was cooled to room temperature. Water (0.5 mL) and NaOH (56.7 mg, 1.421 mmol, 3.0 equiv.) were added, and the reaction mixture was stirred at room temperature for 16 hours and monitored by LCMS until approximately 90.6% of the desired mass was observed. The reaction mixture was diluted with methanol and filtered through a bed of Celite. The filtrate was concentrated under reduced pressure. The crude product was diluted with water (4 mL) and washed with ethyl acetate. The pH of the aqueous layer was adjusted to neutral (6-7) using 1 N HCl. The reaction mass was extracted with 20% MeOH / DCM, and the solvent was evaporated under reduced pressure to give 150 mg of 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-11) as a dark brown solid (yield: 81.4%).1 H-NMR (400 MHz, DMSO-d6) δ ppm: 13.22 (brs, 1H), 8.77 (s, 1H), 8.594 (s, 1H), 8.07 (t, 1H, J= 9.2 Hz), 7.87 (s, 1H), 6.13 (s, 1H), 6.04 (s, 1H), 5.24 (s, 1H), 2.08 (s, 3H), 1.98 (s, 3H); MS (ES) m / z 388.17 (M+H).

[0277] Example 33 Preparation of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CDP-06) from CPD-28 [ka]

[0278] To a stirred suspension of 2',3-dichloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-28) (Example 41, 25.0 g, 1.0 equiv.) in methanol (450 mL, 18.0 vol.) and water (50 mL, 2 vol.), Na2CO3 (9.64 g, 1.5 equiv.) was added to the reaction mass at 25-30 °C and purged with argon gas for 30 minutes. Pd(dppf)Cl2 (2.4 g, 0.05 equiv.) was then added and purged with argon gas for 30 minutes. CO pressure of 60-70 psi (5 Kg) was then applied and the CO pressure was released. The mixture was repressurized with 75-100 psi (7 Kg) CO and slowly heated to 90-95°C and maintained at the same temperature for 24 hours. The progress of the reaction was monitored by TLC / IPC-HPLC. After completion of the reaction, it was cooled to 25-35°C, diluted with water (75.0 mL, 3.0 vol) and stirred for 20-30 minutes. Charcoal (1.25 g, 0.05 T) was then added to the reaction mass and heated to 50-55°C for 1-2 hours. The heating was stopped and the resulting reaction mass was filtered through a hyflo bed, the methanol was distilled off, and the reaction mass was diluted with THF (125 mL, 5.0 vol). Then the pH of the reaction mass was adjusted to 1-2 using 6N HCl (60 mL) at 10-15°C, stirred for 2-3 hours, the solid was filtered, washed with water (75 mL, 3 volumes) and dried at 50°C to give 18.0 g of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-06) as an off-white solid (yield: 70.3%). 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 8.79 (d, J= 10.0Hz, 1H), 8.60 (d, J= 2.4 Hz, 1H), 7.98 (s, 1H), 8.12-8.07 (m, 1H), 6.80 (s, 1H), 5.47 (d, J = 12.0 Hz, 2H), 2.08 (s, 3H), 1.93 (s, 3H); MS (ES) m / z 422.28 (M+H).

[0279] Example 34: Preparation of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CDP-06) from CPD-30 [ka]

[0280] To a stirred suspension of 2'-bromo-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-30) (Example 38, 500 mg, 1.098 mmol, 1 equiv.) in methanol and water (9:1) in a steel bomb, K2CO3 (303 mg, 2.19 mmol, 2 equiv.) and dppf (30 mg, 0.054 mmol, 0.05 equiv.) were added under argon atmosphere at room temperature. The reaction mass was degassed with argon for 10 minutes. Then, Pd(OAc)2 (12.3 mg, 0.054 mmol, 0.05 equiv.) was added under argon atmosphere. The reaction mass was degassed with argon for 5 minutes. The steel bomb was closed, filled with CO gas (100 psi), and opened. The mixture was repressurized with CO gas (100 psi) and the magnetically stirred reaction mixture was heated to 90-95 °C in an oil bath for 20 h. The reaction was monitored by LCMS, which indicated approximately 79.9% of the desired mass. The reaction mixture was cooled to room temperature, diluted with methanol, and filtered through a bed of Celite. The organic layer was concentrated under reduced pressure. The crude compound was placed in a round-bottom flask and then acidified (pH approximately 2) with 1N HCl. The solid was filtered and dried to give the crude desired material, which was purified by preparative HPLC. The combined desired fractions were concentrated under reduced pressure and lyophilized to give 200 mg of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-06) as an off-white solid (yield: 43%). 1H-NMR (400 MHz, DMSO-d6) δ ppm: 13.3 (brs, 1H), 8.81 (s, 1H), 8.60 (d, 1H, J=2 Hz), 8.12-8.06 (m, 1H,), 7.92 (s, 1H), 6.79 (s, 1H), 5.47 (s, 2H), 2.07 (s, 3H), 1.92 (s, 3H); MS (ES) m / z 422.10 (M+H).

[0281] Example 35: Preparation of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CDP-06) from CPD-11 [ka]

[0282] To a stirred suspension of 4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-11) (Example 16, 1.0 g, 2.58 mmol) in IPA (15.0 vol) was heated to 45-50 °C and N-chlorosuccinimide (1.0 equiv.) was added. The temperature was raised to 60-65 °C. After completion of the reaction as indicated by TLC, the reaction mass was cooled to room temperature and then further cooled to 0-5°C, the resulting solid was filtered, washed with IPA (1 volume) and dried to give 0.8 g of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-06) as an off-white solid (yield: 74%). 1H-NMR (300 MHz, DMSO-d6) δ ppm 13.2 (br s, 1H), 8.81 (s, 1H), 8.60 (d, J = 2.7 Hz, 1H), 8.15-8.06 (m, 1H), 7.98 (s, 1H), 6.80 (s, 1H), 5.48 (s, 2H), 2.07 (s, 3H), 1.93 (s, 3H); LC-MS m / z 422.13 (M+H) + .

[0283] Example 36: Preparation of 4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CDP-15) from CPD-03 [ka]

[0284] To a stirred suspension of 2'-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CDP-03) (Example 5, Step 1, 5.0 g, 1.0 equiv.) in toluene (10.0 vol.) was added Na2CO3 (3.0 equiv.). The mixture was degassed with argon gas for 30-45 min. Pd(OAc)2 (0.02 equiv.), Xantphos (0.02 equiv.), and MeNH(OMe) HCl (1.5 equiv.) were added, and the suspension was purged with argon gas for 10-15 min. The temperature was slowly raised to 80 °C and maintained at the same temperature under CO2 pressure (60-70 PSI) for 15 h. The reaction mass was allowed to cool to room temperature and filtered through a celite bed to obtain mL of filtered HCl. They were concentrated under reduced pressure below 50°C to give 4.0 g of 4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CPD-15) as a tan solid (yield: 70%). 1H-NMR (400 MHz, DMSO-d6) δ ppm: 8.65 (brs, 1H), 8.42 (d, 1H, J= 2.4 Hz), 7.53 (s, 1H), 7.31 (m, 1H), 6.02 (dd, 2H, J=2.4 Hz), 5.18 (d, 2H, J= 2 Hz), 3.76 (s, 3H), 3.45 (s, 3H), 2.17 (s, 3H), 1.84 (s, 3H); MS (ES) m / z 431.13 (M+H).

[0285] Example 37: Preparation of 4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CDP-15) from CPD-26 [ka]

[0286] A stirred suspension of 2'-bromo-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-26) (Example 15, Step 2, 500 mg, 1.18 mmol, 1 equiv.) was placed in a steel bomb and suspended in toluene (15 ml, 30 vol.). N,O-Dimethylhydroxylamine hydrochloride (231 mg, 2.36 mmol, 2 equiv.), Xantphos (27.28 mg, 0.0472 mmol, 0.04 equiv.), and KPO (751 mg, 3.54 mmol, 3 equiv.) were added at room temperature under a nitrogen atmosphere. The reaction mass was degassed with argon for 10 minutes. Then, Pd(OAc) (10.62 mg, 0.0472 mmol, 0.04 equiv.) was added under a N atmosphere. The reaction mass was degassed with argon for 5 minutes. The steel bomb was closed, filled with CO gas (50 psi), and opened. The reactor was charged with CO gas (50 psi), and the reaction mixture was magnetically stirred and heated in an oil bath at 100-110 °C for 16 hours. IPC-LCMS showed approximately 65% ​​of the desired mass. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and filtered through a Celite bed. The combined organic layers were concentrated under reduced pressure. The crude product was purified by column chromatography on a 230-400 Si gel using 2-3% methanol / DCM as the eluent to give 250 mg of 4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CPD-15) as an off-white solid (yield: 42%). 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 8.63 (brs, 1H), 8.40 (d, 1H, J= 2.4 Hz), 7.52 (s, 1H), 7.31 (m, 1H), 6.02 (dd, 2H, J=2.4 Hz), 5.19 (d, 2H, J= 2 Hz), 3.76 (s, 3H), 3.44 (s, 3H), 2.17 (s, 3H), 1.86 (s, 3H); MS (ES) m / z 431.06 (M+H).

[0287] Example 38: Preparation of 2'-bromo-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CDP-30) from CPD-26 [ka]

[0288] To a stirred suspension of 2'-bromo-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-26) (Example 15, Step 2, 10 g, 23.69 mmol, 1.0 equiv.) in isopropyl alcohol (150 ml, 15 volumes) was added N-chlorosuccinimide (3.80 g, 28.43 mmol, 1.2 equiv.) at room temperature. The reaction mass was slowly heated to 65-70°C for 2 hours, and during the slow heating, a clear solution formed between 5 and 60°C. When the temperature reached 65-70°C, solid formation was observed in the reaction. Heating was continued at 65-70°C for 2 hours. The progress of the reaction was monitored by TLC until no starting material remained, at which point the reaction mass was cooled to 55-60°C and filtered while hot. The solid was washed with IPA (20 ml, 2 volumes) and dried under reduced pressure at 45° C. for 2 hours to give 5.5 g of 2′-bromo-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2H-[1,4′-bipyridin]-2-one (CPD-30) as an off-white solid (yield: 51%). 1 H-NMR (400 MHz, CDCl3) δ ppm: 8.42 (s, 1H), 8.397-8.391 (d, J= 2.4 Hz, 1H), 7.345-7.297 (m, 1H), 7.27 (s, 1H), 6.37 (s, 1H), 5.404-5.399 (d, J=2 Hz, 2H), 2.055 (s, 3H), 1.973 (s, 3H); MS (ES) m / z 455.96 (M+H).

[0289] Example 39: Preparation of 2'-bromo-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CDP-30) from CPD-31 [ka]

[0290] To a stirred solution of 2'-bromo-3-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-31) (Example 40, 15.0 g, 45.45 mmol, 1 equiv.) in DMF (75 mL, 5 vol.) was added KCO (9.42 g, 68.18 mmol, 1.5 equiv.) under an inert atmosphere. The reaction mixture was stirred at room temperature for 15 minutes, and then 2-(chloromethyl)-3,5-difluoropyridine (INT-01, Example 4) (9.0 g, 54.54 mmol, 1.2 equiv.) in DMF (7.5 mL, 0.5 vol.) was added (dropwise) at room temperature, and the resulting reaction mixture was stirred at 50 °C for 7 hours. The reaction progress was monitored by TLC and LCMS. After the reaction was complete, ice-cold water (25 volumes) was added and stirred for 30 minutes, then the solid was filtered and washed with water. It was dried to give 21.2 g of the desired crude material as an off-white solid. A suspension of the desired crude material (21 g) in methanol (280 mL, 10 volumes) was heated to reflux and stirred for 45 minutes to give a clear solution. It was cooled and stirred at room temperature for 2 hours, and the solid was filtered. It was washed with methanol (28 mL) and dried to give 16 g of 2'-bromo-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-30) as an off-white solid (yield: 77%). 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 8.59 (d, J = 2.4 Hz, 1H), 8.52 (s, 1H), 8.09-8.08 (m, 1H), 7.80 (s, 1H), 6.92 (s, 1H), 5.47 (s, 2H), 1.95 (s, 6H); MS (ES) m / z 455.93 (M+H).

[0291] Example 40: Preparation of 2'-bromo-3-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CDP-31) from CPD-25 [ka]

[0292] To a stirred mixture of 2'-bromo-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CDP-25) (Example 15, Step 1, 15.0 g, 0.0508 mol, 1 eq.) in DMF (255 mL, 15 vol.), N-chlorosuccinimide (8.1 g, 0.061 mol, 1.2 eq.) was added portionwise at 25-30 °C, and the reaction mass was then heated to 72 °C (oil bath) for 4 h. The reaction progress was monitored by TLC and LCMS, which indicated the absence of starting material and the formation of product. The reaction mass was cooled to room temperature, water (300 mL, 20 vol.) was added, stirred for 45 min, and the solid was filtered. It was washed with water (75 mL, 5 vol.) and dried to give the desired crude material (15.1 g). A suspension of the desired crude material (15.1 g) in methanol (900 mL, 60 volumes) was heated to reflux and stirred for 45 minutes to give a clear solution. It was filtered through filter paper, distilled to remove methanol (approximately 80%), stirred at room temperature, and the solid was filtered. It was washed with methanol (75 mL, 5 volumes) and dried under high vacuum to give 10.2 g of 2'-bromo-3-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-31) as an off-white solid (yield: 60.7%). 1 H-NMR (400 MHz, DMSO-d6) δ ppm: 11.59 (s, 1H), 8.49 (s, 1H), 7.75 (s, 1H), 6.15 (s, 1H), 1.94 (s, 3H), 1.85 (s, 3H); MS (ES) m / z 329.58 (M+H).

[0293] Example 41: Preparation of 2',3-dichloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CDP-28) from CPD-03 [ka]

[0294] To a stirred suspension of 2'-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-03) (Example 5, 100 g, 1.0 equiv.) in IPA (1500 mL, 15.0 vol.) was added dichloroacetic acid (8.53 g, 0.25 equiv.) at room temperature. The reaction mass was then slowly heated to 45-50°C, and N-chlorosuccinamide (NCS, 42.4 g, 1.2 equiv.) was added. After the addition of NCS was complete, the temperature was increased to 65-70°C and maintained for 2 h, and a clear solution was observed at 55-60°C. The reaction progress was monitored by TLC and IPC-HPLC. After completion of the reaction, the mixture was cooled to 25-35°C, stirred for 1-2 hours, filtered, washed with IPA (100 mL, 1.0 vol), and dried at 45°C for 2-3 hours to give 89.0 g of 2',3-dichloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CDP-28) with an HPLC purity of 97.66% (yield: 81%). 1 H-NMR (400 MHz, DMSO-d6) δ ppm: δ: 8.43 (s, 1H), 8.396-8.390 (d, 1H, J= 2.4 Hz), 7.321-7.301 (m, 1H), 7.12 (s, 1H), 6.379 (s, 1H), 5.4.4-5.40 (d, 2H, J= 1.6 Hz), 2.074 (s, 3H), 1.974 (s, 3H); MS (ES) m / z 412.07 (M+H).

[0295] Example 42: Alternative preparation of 2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-02) [ka]

[0296] Step 1: Synthesis of N-(2-chloro-5-methylpyridin-4-yl)-2,6-dimethyl-4-oxo-4H-pyran-3-carboxamide (TAUT-01). A stirred solution of 2-chloro-5-methylpyridin-4-amine (SM-01) (100 g, 1.0 equiv.) and 2,2,6-trimethyl-4H-1,3-dioxin-4-one (SM-01) (400 g, 4.0 equiv.) in dimethylacetamide (500 mL, 5.0 vol.) was heated to 110-120 °C and maintained for 4-6 h. The reaction progress was monitored by IPC-HPLC. After completion of the reaction, the reaction mass was cooled to 40-50 °C and quenched with water (15 vol.). The reaction mass was then cooled to 5-10 °C and stirred for 2-3 h. The solid was filtered, washed with water (3 volumes), and dried at 50-55 °C to give 176 g of a brown solid (yield: 85.6%). Based on HPLC data, the ratio of the two compounds, N-(2-chloro-5-methylpyridin-4-yl)-2,6-dimethyl-4-oxo-4H-pyran-3-carboxamide (TAUT-01) to 3-acetyl-2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-01), was 66.2%:31.8%. 1 H-NMR (400 MHz, DMSO-d6): δ ppm.

[0297] TAUT-01: 1 H NMR (dmso-d6) δ 12.34 (s, 1H), 8.30 (s, 1H), 8.20 (s, 1H), 6.49 (s, 1H), 2.74 (s, 3H), 2.34 (s, 3H), 2.26 (s, 3H). CPD-01: 1H NMR (dmso-d6) δ 15.74 (s, 1H), 8.51 (s, 1H), 7.66 (s, 1H), 6.24 (s, 1H), 2.54 (s, 3H), 2.01 (s, 3H), 1.93 (s, 3H), MS (ES) m / z 293.68 (M+H).

[0298] Step 2: Synthesis of 3-acetyl-2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-01). To a stirred suspension of N-(2-chloro-5-methylpyridin-4-yl)-2,6-dimethyl-4-oxo-4H-pyran-3-carboxamide (TAUT-01) (Step 1, 100 g, 1.0 equiv.) in water (1200 mL, 12 volumes), 25% IPA-HCl (3.5 volumes) was added at 25-30°C and stirred for 30 minutes. The temperature of the reaction mass was raised to 80-85°C and maintained for 14-16 hours. After completion of the reaction (by IPC-HPLC), the temperature of the reaction mass was cooled to 5-10°C and stirred for 2-3 hours. The solid was filtered and further purified using IPA and water (1:5) at 25-30°C and dried at 50-55°C to give 75.8 g of 3-acetyl-2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-01) as a brown powder with an HPLC purity of 98.2% (yield: 75.8%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 15.74 (s, 1H), 8.52 (s, 1H), 7.67 (s, 1H), 6.25 (s, 1H), 2.55 (s, 3H), 2.02 (s, 3H), 1.94 (s, 3H). MS (ES) m / z 293.62 (M+H).

[0299] Step 3: Synthesis of 2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-02). 3-Acetyl-2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-01) (Step 2, 100 g, 1.0 equiv.) was added with sulfuric acid (2 volumes) at 25-30 °C, and the resulting suspension was heated to 110-120 °C for 4-6 h. The reaction progress was monitored by IPC-HPLC. After completion of the reaction, the heating was stopped and the reaction mass was cooled to 25-30 °C. The reaction mass was diluted with water (15 volumes), further cooled to 5-10 °C, and the pH was adjusted to 8-9 using aqueous NaOH. The pH of the resulting reaction mass was then adjusted back to 3.5-4.5 using saturated citric acid. The solid thus obtained was filtered and washed with water (3 volumes) and MTBE (5 volumes). The slurry was further purified with DMF (5 volumes) and water (5 volumes) and dried at 50-55°C to give 52 g of 2'-chloro-4-hydroxy-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-02) as a brown solid with an HPLC purity of 99.3% (yield: 60.7%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 10.8 (br s, 1H), 8.47 (s, 1H), 7.55 (s, 1H), 5.97-5.96 (m, 1H), 5.57 (d, J = 2.4 Hz, 1H), 1.96 (s, 3H), 1.83 (s, 3H). MS (ES) m / z 251.52 (M+H).

[0300] Example 43: Kinetic Resolution of Atropisomers of CPD-06 [ka]

[0301] Step 1: Synthesis of (P and M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (S)-1-(naphthalen-2-yl)ethane-1-aminium salt (Isomer 1 A salt and Isomer 2 A salt). To a stirred suspension of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-06) (10 g) in ethanol (20 volumes) in a round-bottom flask, slowly heat to 25-35 °C, and add (S)-(-)-1-2-naphthylethylamine (1.0 equiv.) at 25-35 °C. After addition of the diamine, a clear solution was observed, followed by immediate precipitation), followed by stirring at 25-35°C for 24 hours. The solid was filtered and dried to give 13.7 g of a 1:1 mixture of diastereomeric salts of (P and M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (S)-1-(naphthalen-2-yl)ethane-1-aminium salt (the A salt of Isomer 1 and the A salt of Isomer 2) as a white solid (yield: 97%).

[0302] Step 2: Synthesis of (S)-1-(naphthalen-2-yl)ethane-1-aminium (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (Isomer 1 A salt). A 1:1 mixture of diastereomeric salts of (P and M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (Isomer 1 A salt and Isomer 2 A salt) (Step 1) in toluene (20.0 volumes) was slowly heated to 120-130 °C, and the suspension was maintained for 96 hours. IPC-chiral HPLC shows 96.66%. The reaction was cooled to room temperature, the suspension was filtered, and the solid was washed with MTBE and dried under vacuum to give (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (Isomer 1 A salt) as a white solid. The material was used directly in Step 3.

[0303] Step 3: Synthesis of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-07). The resulting chiral amine salt (S)-1-(naphthalen-2-yl)ethan-1-aminium (Salt A of Isomer 1) (Step 2, 13.0 g) was dissolved in water (6.0 mL), made basic (pH ∼12) with 2 N NaOH, and extracted with MTBE (2 × 10.0 vol). The resulting amine-containing MTBE layer was distilled to give (S)-(-)-1-2-naphthylethylamine with an HPLC purity of 97.41%. The aqueous layer was acidified (pH ∼2) with 2N HCl, resulting in the precipitation of a solid. The precipitated solid was filtered, washed, and dried under vacuum to give 9.36 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-07) as an off-white solid with an HPLC purity of 98.53% and a chiral HPLC purity of 99.77% (yield = 72%). 1 H-NMR (300 MHz, DMSO-d6): δ ppm 13.35 (br s, 1H), 8.80 (s, 1H), 8.60 (d, 1H, J = 2.4 Hz), 8.07-8.12 (m, 1H), 7.97 (s, 1H), 6.80 (s, 1H), 5.47 (d, 2H, J = 1.6 Hz), 2.08 (s, 3H), 1.93 (s, 3H). MS (ES) m / z 422.12 (M+H).

[0304] Example 44: Chiral purification of CPD-20 via simulated moving bed (SMB) chromatography CPD-20 was selected for chiral purification by simulated moving bed (SMB) chromatography. The separation was performed using the parameters shown in Table 4. The final separation operating pressure was 9 bar. Separation of racemic CPD-20 to obtain each atropisomer was demonstrated using a benchtop SMB system with Chiralpak® IB-N, 20 μm as the stationary phase and 50 / 50 DCM / CAN (v / v) as the mobile phase. The SMB system was equipped with eight 10 cm long, 1 cm diameter columns. The atropisomers were separated into two process streams: a raffinate stream (Formula (P)-I) and an extract stream (Formula (M)-I). The compound of Formula (P)-I was recovered in the raffinate stream. [Table 4]

[0305] Feed Preparation: A feed solution was prepared using a CPD-20. A total of 40.3 grams of crude feed was dissolved in 0.8 liters of 50 / 50 DCM / CAN. The solution was tested against a known standard to determine the concentration; 50 g / L.

[0306] Example 45: Kinetic Resolution of Atropisomers of CPD-06 in n-Butanol [ka]

[0307] Synthesis of (P and M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium (Isomer 1 A salt and Isomer 2 A salt). To a stirred suspension of (P and M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (HPLC chiral purity (isomer 1:isomer 2, 98.7%:1.3%)) (Example 43, Step 1, 1.0 equiv.) in 1-butanol (15.0 volumes) was added (S)-2-napthylethylamine (1.0 equiv.) at 25-35°C. The reaction mixture was slowly heated to 110-115°C and stirred at 110-115°C for 40 hours. The progress of the resolution was monitored by chiral HPLC. After completion of the resolution, the reaction mixture was cooled to 25-35°C and stirred at 25-35°C for 3-4 hours. The solid was filtered and dried under vacuum at below 45°C to give 5.5 g of (P and M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylate (S)-1-(naphthalen-2-yl)ethan-1-aminium in chiral HPLC purity (Isomer 1 A salt:Isomer 2 A salt, 99.3%:0.70%) (yield: 78.3%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.66 (s, 1H), 8.60 (d, J =2.0 Hz, 1H), 8.09 (td, J = 2.4, 10.0 Hz, 1H), 7.96-7.88 (m, 6H), 7.78 (s, 1H), 7.63 (d, J = 7.0 Hz, 1H), 7.52 (t, J= 3.6 Hz, 3H), 6.77 (s, 1H), 5.41 (s, 2H), 4.46 (brs, 1H), 2.02 (s, 3H), 1.91 (s, 3H), 1.53 (d, J = 6.4Hz, 3H). MS(ES) m / z 422.28 (M+H).

[0308] Example 46: Alternative Preparation of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CDP-06) from CPD-28 [ka]

[0309] To a stirred suspension of 2',3-dichloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-28) (Example 41, 76.0 g, 1.0 equiv.) in acetonitrile (8.0 vol.) and water (4.0 vol.) was added. After purging with argon gas for 30 minutes, LiCO (3.0 equiv.) was added to the reaction mass, followed by Pd(dppf)Cl (0.5 mol%) and purging with argon gas for 30 minutes. A CO pressure of 40-45 psi (3.0 kg) was then applied and the CO pressure was released. A CO pressure of 100 psi (5.0 kg) was again applied, the mixture was slowly heated to 75 °C, and the mixture was stirred for 48 hours. The progress of the reaction was monitored by TLC / IPC-HPLC, and after completion of the reaction, it was cooled to 25-30°C and degassed with argon. The reaction mass was taken out, water (5.0 vol) was added, and the pH was adjusted to 14 using 2N NaOH solution. The reaction mass was then washed with MTBE (3 times 5.0 vol) and the aqueous layer was filtered through a hyflo bed. The pH of the filtered mL was adjusted to 1-2 using 6N HCl and stirred at 25-30°C for 1-2 hours. The solid was filtered and washed with water (10.0 vol) followed by IPA (1.0 vol) and dried under vacuum to give 67.5 g of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxylic acid (CPD-06) as an off-white solid with an HPLC purity of 98.49% (yield: 86.80%). 1H-NMR (400 MHz, DMSO-d6) δ ppm: 13.35 (br s, 1H), 8.80 (s, 1H), 8.60 (d, 1H, J = 2.4 Hz), 8.07-8.12 (m, 1H), 7.97 (s, 1H), 6.80 (s, 1H), 5.47 (d, 2H, J = 1.6 Hz), 2.08 (s, 3H), 1.93 (s, 3H). MS (ES) m / z 422.28 (M+H).

[0310] Example 47: Alternative Preparation of (P and M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (S)-1-(naphthalen-2-yl)ethane-1-aminium salt (Isomer 1 A salt and Isomer 2 A salt) [ka]

[0311] A stirred suspension of 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-06) (25 g, 1.0 equiv.) in 5% DMSO:anisole (7.04 vol.) was slowly heated to 110-115 °C. Then, 3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (0.025 equiv., seed HPLC chiral purity, isomer I:isomer 2, 99.91%:0.09%) was slowly added to the reaction mass and stirred for 10-15 min, followed by the addition of (S)-2-naphthylethylamine (1.04 equiv., 4.05 g) in DMSO:anisole (14 volumes, 60 mL) at a flow rate (35 mL per hour) using a syringe pump for 20 h. The reaction progress was monitored by chiral HPLC and stirred for 64 h. The mixture was cooled to 25-30 °C and stirred for 1-2 h. The solid was filtered, washed with ethanol (10 volumes), and dried under vacuum to give 32.07 g of (P and M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (S)-1-(naphthalen-2-yl)ethane-1-aminium salt (A salt of Isomer 1 and A salt of Isomer 2) (yield: 91.6%). The salt (32 g) was added to water (10 volumes), the pH was adjusted to 12-14 with 2.0 N NaOH solution, and the aqueous layer was washed with MTBE (3 x 5 volumes). The pH of the aqueous layer was then adjusted to 0.5-1.0 with 6.0 N HCl, and the resulting precipitated solid was stirred for 2-5 hours. The solid was filtered, washed with IPA (1 volume), and dried under vacuum to give 19.0 g of the free acid, (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5′,6-dimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxylic acid (CPD-07) as an off-white solid with an HPLC purity of 99.62% and an HPLC chiral purity of (isomer 1:isomer 2, 99.41%:0.59%) (yield: 83.5%). 1H-NMR (400 MHz, DMSO-d6): δ ppm 13.35 (br s, 1H), 8.80 (s, 1H), 8.60 (d, 1H, J = 2.4 Hz), 8.07-8.12 (m, 1H), 7.97 (s, 1H), 6.80 (s, 1H), 5.47 (d, 2H, J = 1.6 Hz), 2.08 (s, 3H), 1.93 (s, 3H). MS (ES) m / z 422.12 (M+H).

[0312] Example 48: Alternative preparation of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CPD-08) [ka]

[0313] To a suspension of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxylic acid (CPD-07) (117.0 g, 1.0 equiv., Isomer I:Isomer 2, 97.86%:2.14%) in DCM (8 volumes) stirred at -5 to 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC·HCl (1.1 equiv.)) was added at -5 to 0 °C and stirred for 5 to 10 min. TEA (1.0 equiv.) was added at 0 to 5 °C, and the mixture was stirred for 10 to 20 min. N,O-dimethylhydroxylamine hydrochloride (1.5 equiv.) was then added at -5 to 0°C, followed by TEA (1.25 equiv.) at -5 to 0°C, and the mixture was stirred for 1 to 2 hours. The reaction progress was monitored by TLC and IPC-HPLC. After completion of the reaction, ice-cold water (20.0 vol.) was added, the reaction was warmed to 25 to 35°C, stirred for 10 minutes, and the DCM layer was separated. The aqueous layer was extracted with DCM (2 x 5 vol.), and the combined DCM layers were washed with water (5 vol.) and dried over Na2SO4. The DCM layer was completely distilled and co-distilled with MTBE (3 x 3 vol.), followed by precipitation of the residue with MTBE (5 vol.) and stirring for 2 to 3 hours. The solid was filtered, washed with MTBE (1 volume), and dried to give 121.0 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5′,6-trimethyl-2-oxo-2H-[1,4′-bipyridine]-2′-carboxamide with an HPLC purity of 99.13% and an HPLC chiral purity of (isomer 1:isomer 2, 97.14%:2.86%) (yield: 93.86%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.70 (s, 1H), 8.59 (d, 1H, J = 2.4 Hz), 8.04-8.12 (m, 1H), 7.63 (s, 1H), 6.79 (s, 1H), 5.47 (d, 2H, J = MS (ES) m / z 465.31 (M+H).

[0314] Example 49: Alternative preparation of (P)-2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-09) [ka]

[0315] To a stirred solution of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-N-methoxy-N,5',6-trimethyl-2-oxo-2H-[1,4'-bipyridine]-2'-carboxamide (CPD-08) (115.0 g, Isomer 1:Isomer 2 (97.14%:2.86%)) in dry THF (42 vol) was added MeMgCl (1.2 eq; 3 M THF solution) slowly at -10°C to 0°C and stirred for 1 hour. The temperature of the reaction mass was then raised to 0-5°C and maintained for 1 hour. The progress of the reaction was monitored by TLC and IPC-HPLC. After completion, the reaction was cooled to 10%. The reaction was quenched with aqueous ammonium chloride (10 vol). The organic layer was distilled under vacuum below 40°C. Water (2 vol) was added and the reaction was stirred at 25-30°C for 2-4 h. The solid was filtered, washed with water (5 vol), followed by IPA (1.0 vol), and dried under vacuum below 40°C to give 94.18 g of (P)-2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one with an HPLC purity of 96.61% and an HPLC chiral purity of (isomer 1:isomer 2, 98.06%:1.94%) (yield: 90.7%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.83 (s, 1H), 8.59 (d, 1H, J = 2.4 Hz), 8.05-8.14 (m, 1H), 7.89 (s, 1H), 6.79 (s, 1H), 5.47 (d, 2H, J = 1.6 Hz), 2.66 (s, 3H), 2.09 (s, 3H), 1.91 (s, 3H); MS (ES) m / z 420.08 (M+H).

[0316] Example 50: Alternative preparation of (P)-(E)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(3-(dimethyl-amino)acryloyl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-10) [ka]

[0317] To a stirred solution of (P)-2'-acetyl-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-09) (5.5 g, 1.0 equiv., isomer 1:isomer 2, 95.28%:4.72%), N,N-dimethylformamide dimethyl acetal (DMF-DMA (6.0 equiv.)) and DMF (1.0 vol.) were added at 25-35°C. The reaction mass was slowly heated to 50-55°C and maintained at that temperature for 24 hours. The progress of the reaction was monitored by TLC and IPC-HPLC. After completion of the reaction, the heat was turned off and the mixture was cooled to 25-35°C and stirred for 1-2 hours. The solid was filtered, washed with EtOAc (2.0 vol) and dried under vacuum below 40°C to give 4.6 g of (P)-(E)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(3-(dimethyl-amino)acryloyl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one with HPLC 98.74% and HPLC chiral purity (isomer 1:isomer 2, 99.92%:0.08%) (yield: 74.0%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.71 (s, 1H), 8.60 (d, 1H, J = 2.4 Hz), 8.04-8.12 (m, 1H), 7.80-7.86 (m, 2H), 6.78 (s, 1H), 6.37 (d, MS (ES) m / z 475.36 (M+H).

[0318] Example 51: Alternative preparation of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (Formula P-(I)) [ka]

[0319] To a stirred solution of (P)-(E)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(3-(dimethyl-amino)acryloyl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (CPD-10) (4.0 g, 1.0 equiv., Isomer 1:Isomer 2, 99.85%:0.15%) in DMF (6.0 vol.) was added KCO (2.5 equiv.) in small portions, followed by 2-hydroxy-2-methylpropionamidine HCl (INT-02) (3.0 equiv.) at 25-35 °C. The reaction mass was slowly warmed to 45-50 °C and stirred at that temperature for 40 h. The reaction progress was monitored by TLC / IPC HPLC. After the reaction was complete, it was cooled to 25-35°C, diluted with water (15 vol), stirred for 1-2 hours, further cooled to 0-10°C, and stirred for 3-4 hours. The solid was filtered and washed with water (2.0 vol). The solid was then dissolved in DCM (10.0 vol), charged with activated carbon (0.5 T), and stirred at 35-40°C for 1-2 hours. The reaction mass was filtered through a Hi-flow bed and washed with DCM (2.0 vol). The filtered aliquot was distilled under vacuum below 40°C, co-distilled with IPA (2.0 vol), charged with IPA (19.0 vol), then heated to 72-77°C and stirred at 72-77°C for 1-2 hours. The mixture was slowly cooled to 25-30°C, further cooled to 7-15°C, and stirred for 2-4 hours. The solid was filtered and dried under vacuum at below 40°C to give 2.58 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one with an HPLC purity of 99.65% and an HPLC chiral purity of (isomer 1:isomer 2, 98.86%:1.14%) (yield: 60.0%).

[0320] Example 52: Crystallization of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (Formula P-(I)) [ka]

[0321] A stirred suspension of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxy-propan-2-yl)-pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one (Formula P-(I)) (1.0 g, 1.0 equiv., Isomer 1:Isomer 2, 98.86%:1.14%) in IPA (19.0 vol) was stirred at 72-77 °C for 1 h. Seed material (Formula P-(I)) (0.25 g, 0.05 (w / w) fold) was then added at 72-77 °C. Heating was turned off, and the mixture was allowed to cool to 25-35 °C. After stirring for 24 h, the solid was filtered. The solid was washed with IPA (2.0 vol) and dried below 40°C to give 0.8 g of (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)-pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one with an HPLC purity of 99.52% and an HPLC chiral purity of (isomer 1:isomer 2, 99.65%:0.35%) (yield: 80%). 1 H-NMR (400 MHz, DMSO-d6): δ ppm 8.97 (d, 1H, J = 5.2 Hz), 8.86 (s, 1H), 8.69 (s, 1H), 8.61 (d, 1H, J = 2.4 Hz), 8.24 (d, 1H, J = 5.2 Hz), 8.06-8.14 (m, 1H), 6.84 (s, 1H), 5.49 (d, 2H, J = 1.2 Hz), 5.25 (s, 1H), 2.10 (s, 3H), 1.98 (s, 3H), 1.04 (s, 3 H), 1.03 (s, 3H); MS (ES) m / z 514.37 (M+H).

Claims

1. structure 【Chemistry 1】 A process for preparing a compound of formula (P)-I having the formula (a) Compound 【Chemistry 2】 in the presence of dimethylacetamide (DMAc) to give the compound 【Chemistry 3】 to form a mixture; (b) contacting the mixture of (a) with an alcoholic HCl solution to obtain the compound 【Chemistry 4】 forming a (c) converting CPD-01 to formula (P)-I; The method comprising:

2. Compound CPD-01 was 2 SO 4 by contacting the compound 【Chemistry 5】 The method of claim 1 , further comprising forming:

3. Compound CPD-02 【Chemistry 6】 and a base to form the compound 【Chemistry 7】 The method of claim 2 further comprising forming:

4. CPD-03 is contacted with a chlorinating agent to obtain the compound 【Chemistry 11】 The method of claim 3 further comprising forming:

5. CPD-28 is contacted with CO in the presence of a palladium catalyst, a base, and a solvent mixture to produce the compound 【Chemistry 12】 The method of claim 4 further comprising forming:

6. Compound CPD-06 is subjected to chiral separation using a chiral amine and a solvent to obtain compound 【Chemistry 13】 The method of claim 5 further comprising the step of obtaining:

7. 7. The method of claim 6, wherein the chiral amine is selected from the group consisting of (S)-1-(naphthalen-2-yl)ethan-1-amine and (1S,2R)-2-amino-1,2-diphenylethan-1-ol.

8. 7. The method of claim 6, wherein the solvent is selected from the group consisting of toluene, ethylbenzene, n-butanol, anisole, DMSO, or combinations thereof.

9. Compound CPD-07 is contacted with a solvent, MeNHOMe, an amine base, and a coupling reagent to obtain compound CPD-07. 【Chemistry 19】 The method of claim 6 further comprising the step of obtaining:

10. Compound CPD-08 is contacted with MeMgX to obtain compound 【Chemical 22】 The method of claim 9 , further comprising the step of obtaining:

11. Compound CPD-09 is condensed with N,N-dimethyl-formamide dimethyl acetal to give compound 【Chemistry 25】 The method of claim 10 further comprising the step of obtaining:

12. Compound CPD-10 in the presence of a base 【Chemistry 26】 and forming a compound of formula (P)-I; The method of claim 11 further comprising:

13. (a) contacting compound CPD-03 with a vinyltin reagent in the presence of a palladium catalyst to form a mixture; (b) contacting the mixture of (a) with HCl to produce the compound 【Chemistry 31】 forming a The method of claim 3 further comprising:

14. Compound CPD-03 is contacted with butyl vinyl ether in the presence of a palladium catalyst, a phosphorus reagent, and a base to obtain compound CPD-03. 【Chemical 33】 The method of claim 3 further comprising forming:

15. Compound CPD-27 is contacted with an acid to produce compound 【Chemical 34】 The method of claim 14 further comprising forming:

16. Compound CPD-17 is contacted with a chlorinating agent to obtain compound 【Chemistry 35】 The method of claim 13 further comprising forming:

17. Compound CPD-18 is condensed with N,N-dimethyl-formamide dimethyl acetal to give compound 【Chemical 36】 The method of claim 16 , further comprising the step of obtaining:

18. Compound CPD-19 in the presence of a base 【Chemical 37】 and compound 【Chemical Formula 38】 forming a 20. The method of claim 17, further comprising:

19. 19. The method of claim 18, further comprising subjecting compound CPD-20 to chromatographic separation to obtain the compound of formula (P)-I.

20. 20. The method of claim 19, wherein the chromatographic separation comprises simulated moving bed (SMB) chromatography with a chiral stationary phase and a mobile phase.

21. 21. The method of claim 20, wherein the mobile phase is dichloromethane and acetonitrile.

22. 【Chemical Formula 124-1】 【Chemistry 124-2】 or a salt thereof, or a co-crystal thereof.

23. The method of claim 20, wherein the mobile phase is acetonitrile and methanol.

24. The compound CPD-17 is contacted with a chlorinating agent to obtain the compound The method of claim 15 further comprising forming:

25. The compound CPD-18 is condensed with N,N-dimethylformamide dimethyl acetal to obtain the compound 25. The method of claim 24, further comprising the step of obtaining:

26. Compound CPD-19 in the presence of a base and compound forming a 26. The method of claim 25, further comprising:

27. The method of claim 26, further comprising subjecting compound CPD-20 to chromatographic separation to obtain a compound of formula (P)-I.

28. The method of claim 27, wherein the chromatographic separation comprises simulated moving bed (SMB) chromatography with a chiral stationary phase and a mobile phase.

29. The method of claim 28, wherein the mobile phase is dichloromethane and acetonitrile.

30. The method of claim 28, wherein the mobile phase is acetonitrile and methanol.

31. A compound comprising 23. The compound of claim 22, or a salt thereof, or a cocrystal thereof.

32. The compound of claim 1, 23. The compound of claim 22, or a salt thereof, or a cocrystal thereof.

33. The compound of claim 22, 23. The compound according to claim 22, or a salt thereof, or a cocrystal thereof.

34. The compound comprising:

23. The compound of claim 22, or a salt thereof, or a cocrystal thereof.

35. The compound of claim 34, 23. The compound of claim 22, or a salt thereof, or a cocrystal thereof.

36. The compound is a salt A of isomer 1. (Isomer 1A Salt) 23. The compound of claim 22, or a salt thereof, or a cocrystal thereof.

37. The compound of claim 36, 23. The compound of claim 22, or a salt thereof, or a cocrystal thereof.